MHC Class I Antigen Presentation is Regulated by the SUMO-Conjugating Enzyme UBC9: a Dissertation by Shen, Yuelei
University of Massachusetts Medical School 
eScholarship@UMMS 
GSBS Dissertations and Theses Graduate School of Biomedical Sciences 
2003-06-01 
MHC Class I Antigen Presentation is Regulated by the SUMO-
Conjugating Enzyme UBC9: a Dissertation 
Yuelei Shen 
University of Massachusetts Medical School 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/gsbs_diss 
 Part of the Amino Acids, Peptides, and Proteins Commons, Biological Factors Commons, Cells 
Commons, Enzymes and Coenzymes Commons, and the Genetic Phenomena Commons 
Repository Citation 
Shen Y. (2003). MHC Class I Antigen Presentation is Regulated by the SUMO-Conjugating Enzyme UBC9: a 
Dissertation. GSBS Dissertations and Theses. https://doi.org/10.13028/vt30-sg28. Retrieved from 
https://escholarship.umassmed.edu/gsbs_diss/111 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in GSBS Dissertations and 
Theses by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
MHC CLASS I ANTIGEN PRESENTATION IS REGULATED BY SUMO-
CONJUGATING ENZYM - 9
A Dissertation Presented By
Yue-Lei Shen
Submitted to the Faculty of the
University of Massachusetts Graduate School of Biomedical Sciences
Worcester
in parial fulfilment of the requirements for the degree of:
DOCTOR OF PHIOSOPHY IN IMOLOGY AN VIOLOGY
June 2003
MHC CLASS I ANTIGEN PRESENTATION IS REGULATED BY THE SUMO-
CONJUGATING ENZYME UBC9
A Dissertation Presented
By
YUELEI SHEN
Kenneth Rock, Dissertation Mentor
Anthony Carruthers, Dean of the
Graduate School of Biomedical Sciences
Department of Pathology
June 11, 2003
Approved as to style and content by:
Leslie Berg, Chair of Committee
Michael Brenner, Member of Commttee
Janet Stavnezer, Member of Committee
Lawrence Stern, Member of Committee
Raymond Welsh, Member of Committee
COPYRGHT NOTICE
Pars of this dissertation gave been presented in the following publications
York IA, Mo AX, Lemerise K, Zeng W, Shen Y, Abraham CR, Saric T, Goldberg AL
Rock KL. (2003) The cytosolic endopeptidase
, thimet oligopeptidase, destroys antigenic
peptides and limits the extent of MHC class I antigen presentation. Imunity. 18(3): 429-
40.
Shen YL, York IA, Rock KL (2003). MHC class I antigen presentation is regulated by
ubiquitin conjugating enze UBC9. In preparation.
Acknowledgements
Here, I would sincerely thank my wife, Jian Ni, for her persistent support and
encouragement, and my baby Jacqueline Ming Shen, who brought me so much happiness.
Could I say that she also have given me huge amount of support?
I have too much thanklness to my mentor, Dr. Kenneth L. Rock, for his kind guidance
and support. He has been so deeply needed not only in my research but even in my life.
What can I say to him? He has been far beyond the best mentor to me, the one I wil
remember forever, the memory he has brought to me wort being cherished forever.
I also want to thank Dr. Ian A. York. Since I came to Rock lab
, I have been working
together with Ian. He is the one from whom you can lear more than you want to. Feel so
free to discuss- my every tiny piece of data with hi. Every time when I feel disappointed
I know from where to get encouragement. What a good experience. I do not know whether
I can stil fid such a mentor-like parer in the futue. Maybe I am too dependent.
Here I want to than all the members in the Rock lab. No matter what I wanted to lear
, no
matter what problem I met, you guys were always there. I would give my than to all of
you, thans for all the happy memories with you.
At last, I wil thank my committee member, Drs. Raymond M Welsh, Leslie J. Berg and
Janet M. Stavnezer, for your suggestions and comments in my thesis research.
Table of Contents
Abstract. . 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ... . . . . . . . . . . . . . . . . . . . . ...
Chapter I: Introducti
........ ................................... .....  '''''' ....
1. The pathway ofMHC class I antigen presentation. ...................................
1.1 Most peptides in cell are generated by proteasomes in the cytoplasm..... .....
1.1 The main source for generating MHC class I bound peptides:
DRiPs or native proteins?......................................................... ...
1.1 Proteasome composition is changed in IFy-treated cells.......................
1.4 Cytosolic proteases are involved in peptide trmmg........................ ....
1.5 TAP transports peptides into ER... .. .. 
. .  .  . .. .. .. .. . . .  .  "" .  .. . ..
1.6 Missing steps between peptide generation and TAP transportation.. ...... . ...
7. ,Aminopeptidases may trm longer peptides to the correct
size in ER lumen. . 
" . . . . .   . .. . . . . . . . . .. . . . . . . . . . . . .. . . . . .   . . . . .
1.8. ER chaperones facilitate MHC class I complex assembly........... ....... ....
9. Some pathogens can evade the MHC class I antigen
presentation pathway. . 
. . .          . . . . . . .  . . . . .  .  . . .     . . . . . .  . . . .  .  . 
Ubiquitin-conjugating enzes are involved in protein degradation........ .
Ubiquitin conjugating enze (Uc) 9..... ........... ............... ...... .......
UBC9 is an E2-like molecule.. 
.. """'"  .  
Sumoylation is an enzatic process very simlar to ubiquitination. 
.  
4. Object of ths project..................................................... ......... 
" "''
Chapter II Materials And Methods.......... 
............ ........ ... ........ .... :....... ...... .
Chapter III. Results..................... 
.... . ...... ... . ... ... .. . . . .
1. UBC9 overexpression increases surac SIINEKL levels.......
.45
1. UBC9 overexpression increases surace H-
expression........ .45
1.2. UBC9 increases H- SIINEKL expression on cells
transfected with all forms of SIINFEKL precursors.. 
""  . .  .  .
.47
1.3. UBC9 effects on stable ovalbumin transfectants .....................
1.4. UBC9 does not increase H- SIINEKL levels by
enhancing the synthesis of ovalbumin................................. .
5. UBC9 does not increase MHC class I antigen presentation
by increasing degradation of antigenic proteins. . 
     . .  .    .  .. . 
1.5. Ovalbum protein degradation is proteasome dependent........... .
2. Analysis ofUBC9 effects on oligopeptide constrcts..................... .....
1. UBC9 overexpression regulates proteasome-
dependent presentation. . 
 .  . .  .   . . .. .  . . .   . . . . .   . .   . . .     
2. Ubc9 overexpression enhances N-terminal extended
peptide presentation. . 
. .   .   . .  .   . .  .   . . '" . . . .  .  .    .
2.3. UBC9 overexpression increases SIINEKL peptide
Presentation...........
: . .
2.4. UBC9 affects ER processes...... ... 
2.5. ICP47 does not affect UBC9 fuction in regulatig
ER-tageted miigene presentation ................
;.
6. UBC9 overexpression increases H- STIEKL level
on E36- cells transfected with all forms ofSIINFEKL
mingenes. . 
. . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . ..
3.3. UBC9 does not regulate MHC class I antigen presentation by
regulating aminopeptidases or protecting peptide from degradation. . 
 . .
3.3. 1. UBC9 does not regulate aminopeptidases............................. 72
3.3.2. UBC9 does not regulate MHC class I antigen presentation
by protecting peptide from degradation......... ....... '" 
. ...  .
3.4. UBC9 overexpression increases the levels of several proteins
in the antigen presentation pathway..... 
............ ... """"""
3.4. 1. UBC9 upregulates imunoproteasome components.............. ....
3.4.2. UBC9increases TAPI and Tapasinprotein levels....................
3.4.3. UBC9 inhibits degradation of some proteins in the
MHC class I presentation pathway. . 
  . . .   . .. . .  . .  . . . . . .  . .   . . . .  ..
siRNA-mediated elimination ofUBC9 does not decrease
MHC class I antigen presentation...................
; .
Interferon treatment decreases UBC9 expression....... . 
 .
SUMO-2 may be involved in UBC9 regulation ofMHC
class I antigen presentation...................................... ............. ...
Chapter IV: Hsp27 Affects Mhc Class I Antigen Presentation.. . 
. . . . 
101
1 HSP27 overexpression reduces H - SIINEKL levels. . . 
 . . . .
10 1
2. Mutation of potential SUMO conjugation and phosphorylation
sites does not affect HSP27's effect on MHC class I antigen
iii
presentation;....................................................... ........... 
..... .
103
4.3. HSP27 knockout decreases MHC class I antigen presentation...... "'"'' .. 107
Chapter V: Discussion........................................................... ....... ...... 113
1. UBC9 overexpression increases antigen presentation....................... . 113
1.1. UBC9 affects multiple steps in MHC class I antigen
presentation. . 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .... .. . .. ... .
. 114
2. Does UBC9 increase peptide translocation from the
cytosol to the ER lumen? 
...................... ..... . .
117
1.3. How does UBC9 work?............................................. ....... 122
1.4. SUMO-2 may be involved in MHC class I antigen
presentation regulation................................................... . 123
5. Model for UBC9 regulating MHC class I antigen
Presentation................................................................ . 125
1.6. UBC9 knockout does not decrease H- SIINEKL level....... 130
7. Biological significance.................................................. .. 132
2. HSP27 overexpression inibits MHC class I antigen presentation...... .... 134
Appendix................................................ '
"''''''''''''''''''''''""""",,, 
141
Reference. . . 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .   .  . . .    .    . . . . . . . . .    .   . .  .   . . . 
143
iv.
Abbreviations
cDNA
C02
DMEM
DMSO
FACS
FBS
GFP (EGFP)
H2O
HCM
HLA
HPLC
HSP
IL-
MACS
MHC
NaCI
NaOH
Ova
PBS
PCR
PSA
SDS
siRA
SUMO
TAP
TCA
TFA 
TOP
Tris
UBC
Bleomycin hydrolase
Complementary DNA
Carbon dioxide
Dulbecco s Modified Eagle Medium
Dimethyl sulfoxide
Endoplasmic reticulum
Fluorescence-activated cell sorting
Fetal Bovine Seru
(Enhanced) green fluorescent protein
Water
Hybridoma cultue medium
Human leukocyte-associated antigen
High Pressure Liquid Chromatography
Heat shock protein
Interleuke-
Magnetic bead activated cell sortng
Major Histocompatibility Complex
Sodium Chloride
Sodium hydroxide
Ovalbumin
Phosphate buffered saline
Polychain reaction
Puromycine sensitive amiopeptidae
Sodium dodecyl sulfat
Short-interferig RNA
Small ubiquitin-like modifier
Transporter associated protein
TricWoroacetic acid
Tris-EDT A
Trifluoroacetic acid
Thimet oligopeptidase
Tris(hydroxymethyl) amiomethane
Ubiquitin conjugating enze
ABSTRACT
CD8 T cells recognize complexes of MHC class I and peptide on the surace 
target cells , MHC class I antigen presentation is a long pathway, in which proteins are
degraded by proteasomes to generating oligopeptides
, which may be fuher trmmed by
amiopeptidases in the cytosol. Peptides are transported into the ER
, where they may be
fuher trmmed by ER lumenal aminopeptidases and bind to newly-synthesized MHC class
I complexes. Proteins degraded by the proteasome are generally tagged with ubiquitin by a
combination of ubi quit in-conjugating enZyes and ubiquiti ligases. UBC9 is one ubiquitin
conjugating enze, which does not conjugate ubiquitin
, but instead conjugates small
ubiquitin-like molecules (SUMO) to taget protein. UBC9 has been found 
to regulate the
fuctions of many proteins in vivo
, most importtly by modifyg 
nuclear transportation
and fuction. Curng my thesis work
, I studied the fuction ofUBC9 in MHC class I
antigen presentation.
UBC9 over-expression in COS cells co-expressing ovalbumn markedly increased
presentation SIIEKL (the imunodomiant epitope from ovalbum in the context ofH-
), and UBC9 overexpression increased cell surace H- b in general
, suggesting that
Ubc9 increased MHC class I antigen presentation by increasing peptide supply.
UBC9 did not increase synthesis or degradation of ovalbum. In transient
transfection experiments
, Ubc9 increased presentation of SIINEKL precursors that did, and
that did not, depend on proteasomes for processing, as well as SIINEKL precursors
targeted to the ER, bypassing cytosolic processing altogether. However
, a C-termnal
extended precursor of SIINEKL
, which req\,es only proteasomal processing before
presentation, was the most markedly affected by UBC9 overexpression. This suggested that
UBC9 was affecting the pattern of cleavages made by proteasomes in ways that enhance the
generation of the C-terminus of SIINEKL. Because presentation of STIEKL itself
(which requires no fuher proteolytic processing) was also enhanced
, UBC9 must also
affect steps in the class I pathway that occur after the generation of the 
matue epitopes.
UBC9 did not affect the rate of peptide degradation in cytosolic extracts or in intact cells.
These findings suggested that UBC9 might have multiple effects on the MHC
class I antigen presentation pathway. Imunofluorescent microscopy demonstrated that
UBC9 increased the expression of the beta subunts of immunoproteasomes (LMP2
, LMP7
and MECL 1) as well as of TAPI and tapasin. In contrast UBC9 expression did not increase
levels of calnexin, calreticulin, ERp57, or Protein disulfide isomerase (PDI). Simlarly,
levels of leucine amopeptidase were not increased in UBC9-transfected cells. Therefore
UBC9 overexpression increases the levels of some but not all components of the class I
pathway.
UBC9 overexpression increased protein levels ofMECLl
, LMP2 or LMP7 that were
under the control of viral promoters
, and levels of MECL mRA were similar in control
vector and UBC9 transfected cells. Therefore
, UBC9 did not increase the level of
expression of these subunits through increased transcription. Pulse-chase experiments
showed that UBC9 overexpression reduced the degradation of MECL 1. Therefore
, UBC9
increases the levels of at least some of these components ofthe MHC class I antigen
presentation pathway by increasing their stability.
To know the biological significance ofUBC9 in MHC class I antigen presentation
, I
used small interferig RNA (siRNA) to knock down UBC9. Though UBC9 can be
successfully knocked down by siRA
, the UBC9-negative cells became very sick
, and were
not suitable for the study of MHC class I antigen presentation.
There are three forms of SUMO molecules in mamalian cells: SUMO- , SUMO-
and SUMO-3. My study suggested that SUMO-2 may be involved in UBC9' s regulation of
MHC class I antigen presentation
, since mutant SUMO-2 blocked UBC9' s ability to
increase H- SIINEKL levels on the cell surface after the cells were loaded with
ovalbum.
To fuher study the fuction ofUBC9 , I mutated the active amno acid Cys 93 
UBC9 to Ser (UC90H). Unexpectedly, ths mutant form (UC90H) has very similar
effects as wild-tye UBC9, increasing K SIINEKL levels at the cells surface. Ths
suggested that UBC9 protein regulates MHC class I antigen presentation pathway proteins
by direct or indirect protein interaction
, rather than (or as well as) by SUMO conjugation.
Takg account of SUMO-2 results, I propose that wild-tye UBC9 (either transfected or
endogenous) conjugates SUMO-2 to its substrates, and then UBC9 (wild-tye or mutant)
interacts with its sumoylated targets
, thus affecting protein fuctions.
.:y
I also studied heat shock protein Hsp27
, which is known to be a substrate for
UBC9 in vivo. Hsp27 is expressed in a varety of tissues in the absence of stress, and may
regulate actin dynamics.
Hsp27 overexpression decreased generation ofH- SIINEKL complexes
from SIINFEKL precursors that did, and did not, require proteasomes for processing, or that
, were targeted to the ER. Hsp27 over-expression did not affect protein synthesis
, and
globally decreased cell surace H2- and H2- levels, but did not affect HLA-A0302
level. Hsp27 overexpression inbits the presentation ofER-localized SIINEKL. Taken
together, my datasuggested that HSP27 may inhbit MHC class I antigen presentation by
affecting MHC class I molecules itself rather than peptide supply.
After Hsp27 was eliminated with siRNA
, the effects were very similar to those
seen with Hsp27 overexpression. Levels ofH- SIINEKL decreased, and overall cell
surface H- and H- levels decreased. It is possible that when Hsp27 is over-
expressed, it acts as a domiant negative form, conferrg a similar phenotye to Hsp27
knockdown. These observations suggest that Hsp27 plays an important role in MHC class I
antigen presentation.
CHAPTER I: INTRODUCTION
In the battle between the immune system and infectious agents
, T cells screen 
class I-peptide complexes on the cell surface. When T cells find foreign peptides bound to
MHC class I molecules , they are activated, proliferate, and destroy the infected or mutant
target cells. In the MHC class I antigen presentation pathway, proteins are degraded by
proteasomes into oligopeptides that are transported into the ER. Many oligopeptides are too
long for MHC class I binding and these oligopeptides generally can be fuer trmmed 
appropriate size by amnopeptidases in the cytosol or ER. In the ER lumen
, 8-10-residue
long peptides bind to empty MHC class I heavy chain132-microglobulin complexes with the
help of tapasin and chaperones, including GRP78 , calnexin, calreticulin, and ERp57. These
chaperones are also thought to help proper folding and assembly of MHC class I molecules
and stablize empty MHC class I molecules. After bindig peptide, complexes are then
transported to the cell surace. T cell receptors (TCR) on CD8+ CTL recognze the MHC
class I heavy chain132m/peptide complexes at the cell surace. Many factors are involved in
regulating MHC class I antigen presentation
, includig cytokines such as interferon-
(IFy).
The pathway of MHC class I antigen presentation.
1.1 Most peptides in cell are generated by proteasomes in the cytoplasm
1 ,
It has long been known that most MHC class I-bound peptides are generated in the
cytosol (although some peptides are generated in the ER (1)). For example
, Townsend et al.
expressed influenza virs haemagglutinin (H) in the cytoplasm by deleting the ER leader
signal sequence, and found that the HA epitope was still presented on MHC class I
molecules (2, 3). However, the main protein processing machiery for the generation of
MHC class I-bound peptides was a mystery for a very long time. Due to the abundance 
proteases in the endosome/lysosome
, it was intially thought that lysosomal proteases might
be key players in generating MHC class I bound peptides. However
, when inhibitors of the
lysosomal proteases (such as weak bases
, leupeptinor E64) were used to block proteolysis in
endocytic comparents, MHC class I antigen presentation was not affected (4
, 5).
Therefore, unike peptides that bind to MHC class II molecules, most MHC class I peptides
must not be generated in endosomes or lysosomes.
Another major protease involved in protein degradation is the proteasome
, an A TP-
dependent protease complex in the cytosol. Proteasomes are responsible for degrading
many proteins , especially ones that have been conjugated with poly-ubiquitin (which is a 76
amio acid-long protein (6) (see below). Two tyes of pro tea somes can be purfied from
cells, the 20S and 26S complexes. The 20S complex is a 28 subunt paricle
, which forms a
four rig strctue (7). Seven homologous l3-subunits compose the two iner rigs, while
another seven homologous a rings make up the two outer 
rigs. Basically the two iner
rigs are responsive for proteolysis, in which three of the l3-subunts (131
132, and 135) are
most importnt (8). The 26S proteasome is a very large paricle composed of20S (650-
kDa) proteasome and two 19S (700-kDa) regulatory complexs, which are located at each
6. H
end of the 20S core paricle (9). The 26S complex requires ATP to degrade proteins and is
believed to be the pricipal form of the paricle which degrades proteins in vivo. Ths larger
complex is the only one that can degrade poly-ubiquitinated proteins.
The discovery of the proteasome components LMP2 and LMP7 in the MHC class II
region of the genome suggested a role for proteasomes in MHC class I antigen presentation
(10- 13). Using cells that exhibit a temperatue-sensitive defect in ubiquitin conjugation
Michalek et al. found that at the non-permssive temperatue MHC class I -restricted
presentation of ovalbum introduced into the cytosol was inibited
, but presentation of an
ovalbumn peptide synthesized from a minigene
, which does not requie proteolysis for
presentation, was not affected. Since proteasomes are required for polyubiquitinated protein
degradation, this fmding suggested that proteasomes are required for MHC class I antigen
presentation (14). Another line of evidence showing that the proteasome is involved in
generating peptides for antigen presentation involved altering the rate of degradation of an
antigenic substrate by the proteasome. Protein stability is affected by the N-end rule
, in
which its N-termal amino acid affects the rate of ubi qui tin at ion and degradation by
proteasomes (15). By modifying beta-galactosidase with a destabilzing amino-terminal
residue, Grant et al. found that the rate of MHC class I presentation of a l3-gal derived
peptide was enhanced. This enhanced presentation was inbited by blockig potential
ubiquitination sites on the protein through methylation of epsilon amo groups, and by
peptide aldehyde inbitors of the proteasome (16). Yet another line of evidence for the role
of the proteasome in antigen presentation involved the use of pro tea some inbitors. When
cells were treated with these agents
, both protein degradation and the generation of most
':..
";'''.
presented peptides was blocked (5, 17). Therefore, proteasomes catalyze the degradation of
the vast majority of cell proteins and generate most peptides presented on MHC class I
molecules.
1.2 The main source for generating MHC class I bound peptides: DRiPs or native
proteins?
It was originally thought that class I -presented peptides were derived from the
degrdation of full length proteins. However, recent work has suggested that defective
ribosomal products (DRis) may be the main source of pep tides to MHC class I molecules
(18). According to this hypothesis, many newly synthesized polypeptides never attain their
native strctues owing to errors in translation or in post-translational processes necessar
for proper protein folding (19-21). These incomplete or abnormal proteins are rapidly
degraded by the proteasome
, generating the class I -presented peptides. A more recent study
also suggested that newly made proteins are requied for MHC class I antigen presentation
for long-lived proteins (22). In their work
, they utilized lymphocytic choriomeningitis virs
(LCMV nucleoprotein, which has a half-life of).3 days , as a model protein. Two days after
nucleoprotein expression was induced
, they termnated protein expression
, and found that
the cells rapidly ceased antigen presentation
, although the protein was stil present and
presumably being degraded by proteasomes. This result supported the DRis theory. This
process might be advantageous as a mechansm to insure rapid MHC class I-restrcted CTL
responses after cell mutation or infection. Although all proteins are continuously degraded
there might be a delay between the synthesis and degradation/presentation of relatively
g.. -
stable proteins durg which time pathogens could multiply. Although ths theory may
explain how many peptides are generated for MHC class I molecules
, ths canot be the
whole story. When matue ovalbumin protein is introduced directly into the cytoplasm of
cells by the osmotic lysis of pinosomes, it is degraded and its epitopes are presented by
MHC class I molecules (3). In our experients
, when cells are diectly loaded with full
length ovalbumin antigen (which is rapidly degraded), we can detect H2- SIINEKL
complexes on cell surace in only half an hour. Since in this system there is no synthesis of
ovalbumn, protein synthesis is clearly not absolutely lined to antigen presentation. The N-
end rule also suggested that the protein degradation rate of newly synthesized 
matue
proteins is crucial for peptide generation (because DRiPs are presumed to all be very rapidly
degraded) (23 , 24). MHC class T presentation can be inibited by blocking potential
ubiquitination sites on the protein though methylation of amino groups (16). So it is not
presently known how important or in what situations DRis playa role in generating
presented peptides.
1.3.Proteasome composition is changed in IFy-treated cells.
It has long been known that IFy treatment up-reguates MHC class I antigen
presentation. IN-g increases the expression of most of the known components of the class I
pathway, inCluding the class I heavy and light chain and the TAP transporter. In addition
three proteasome subunts, LMP2 (MBl), LMP7 (6) andMECL- l (LMPIO), have been
found to be induced by IFNy and to replace
, respectively, the constitutive proteasome
subunits 131
, 132, and 135 (25 26). The resulting paricle is called the "imunoproteasome
...
' . . :
(27). Immunoproteasomes and constitutive proteasomes have very different proteolytic
activity and often result in different cleavage patterns on the same antigen (28 29). LMP2 '
and LMP7 are encoded in the mammalian MHC locus (30
, 31). Early experients showed
that LMP2 and LMP7 were not essential for generating peptides for MHC class I antigen
presentation (10). Subsequently, however
, it was found that LMP gene products specifically
alter the peptidase activities of the proteasome
, which in tu alters the peptide profiles on
MHC class I molecules (12, 13). This is because these 3 imunoproteasome subunts
encode the active proteasome s active sites. Both LMP2 and LMP7 knockout mice and
cells lackig these subunits showed decreased rates of cleavage after hydrophobic and basic
residues and increased hydrolysis after acidic ones. Overexpression of LMP2 and LMP7 had
the opposite effects. Ths change in cleavages should generate more peptides that end in
hydrophobic and basic residues
, which are the precisely the kid of peptides found on MHC
class I molecules (32 , 33). Loss ofLMP2 or LMP7 reduces the presentation of certain
epitopes. In contrast, overexpression of LMP2 , LMP7 and MECL- l has been found to
increase presentation of the LCMV imunodominant epitope (34).
Recent fmdigs suggested that the incorporation of IFNy inducible proteasome subunits
not always enhance antigen presentation
, but also may reduce the generation of certain CTL
epitopes (35). For example, Morel et al. found that an EBV antigen
, RUl , canot be
processed by immunoproteasomes but can be processed by standard proteasomes (27
, 36).
It seems that imatue, but not matue, dendrtic cells can present the RUI epitope to CTL
which is consistent with the fmdig that matue DC express only immunoproteasomes while
imatue DC express both standard and imunoproteasomes (37, 38).
ID,
IFNy treatment affects other associated components of the proteasome in addition to the
catalytic beta subunts. An 11 S heterohexameric or heteroheptaeric complex, which is
composed of two homologous subunts
, P A28a and P A2813, is a regulatory complex of the
20S proteasome. Both P A28a and P A2813 subunts are markedly increased upon IFNy
treatment, suggesting its involvement in antigen processing and MHC class I antigen
presentation. Overexpression ofPA28a in a mouse fibroblast line expressing the mure
cytomegalovirs pp89 protein has been found to markedly enhance its recogntion by pp89-
specific cytotoxic T cells (39). Also, mice deficient in P A2813 gene have defects in antigen
presentation (40). In one study, the assemblyofimunoproteasomes (containg LMP2
LMP7 and MECL- l) was greatly impaired in these P A28j3 deficient mice, suggesting that
PA28 was required for immunoproteasome assembly. In contrast to the fmdings with the
P A2813 knockout mice, in P A28a/P A2813 double knockout mice imunoproteasomes were
induced upon IFy treatment (41), possibly suggesting that loss of P A28a itself may impair
immunoproteasome assembly. Although imunoproteasomes are assembled in
A28a/P A2813 double knockout mice, these mice have defects in processing a melanoma
antigen TRP2 , but not in processing ovalbum or influenza A virus, suggesting that
A28a/P A2813 complexes affect the processing of certain antigens but not others.
1.4. Cytosolic proteases are involved in peptide tring
To fit into the MHC class I molecule peptide-binding cleft, peptides must be 8-
residues in length (8, 42). In vitro experiments results suggest that mammalian 20S and 26S
u",
proteasomes generate peptide products ranging from 3 to 22 amo acids (43) durg
degradation of different proteins (44, 45). Using ovalbumin as a model protein
, Cascio et al.
found that 26S and 20S proteasomes generated
, as well as products shorter than 8 amino
acids, SIINEKL itself as well as peptides containing 1-7 extra N-terminal residues
preceding SIINEKL, while immunoproteasomes released 2-4 times more of certin 
extended versions, but no more of the correct-sized peptide SIINEKL (29). These N-
extended peptides would have to be fuer processed for tight binding to MHC molecules
or else just ignored by antigen presentation.
Much work has been done in our lab and others to study whether proteasomes are
necessar in trmming longer peptides to the correct size. When migenes encodig
SIINEKL peptides with several extra N-termnal residues were introduced into cells
SIINEKL can be efficiently presented by H- cells in the presence of pro tea some
inbitors. However, if even one extra residue exists at the C-termal of peptides
SIIEKL presentation is inbited by proteasome inbitors (46
, 47). In addition
acetylation of the amino termus of an extended constrct, which prevents trng 
aminopeptidases (but not endbpeptidases), prevents the presentation of these peptides (47).
These results suggest that the C terminus of antigenic peptides must be generated by the
proteasome, but that other proteases, particularlyaminopeptidases
, can also generate the N-
termini.
The fIrst aminopeptidase' specifically implicated in antigen processing was leucine
aminopeptidase (LAP) (48). N-termnal tring was found to be several-fold faster in
12.",
cytosolic extracts ofIF-y treated cells then that of untreated cells, and the IF-inducible
activity was found to be LAP. Purfied LAP quickly trmmed the II-mer QLESTIEKL
peptide to SIINEKL in vitro. Very interestingly, LAP expression is enhanced by IF-
treatment, suggesting that ths aminopeptidase is involved in peptide trmmng and MHC
class I antigen presentation. More recently, puromycin-sensitive aminopeptidase (PSA) and
bleomycin hydrolase (BH) have also been found implicated in peptide trg. These two
proteases could remove NH terminal amino acids from the vesicular stomatitis virs
nucleoprotein cytotoxic T cell epitope 52-59 (RGYVQGL) in cells not treated with IFN-
(49). Besides these cytosolic aminopeptidases
, an ER lumen-resident aminopeptidase
(ERAPl) has recently been found, and ths wil be discussed in detail below.
1.5 TAP transports peptides into ER
Most peptides for MHC class I antigen presentation are generated in the cytosol
, and
then transported into ER, where they bind to empty MHC class I molecules. Defitive
evidence that these peptides are generated in the cytoplasm came from the analysis of
mutant cells lacking the transporter associated with antigen processing (TAP). TAP
deficient human cell line LBL 721.174 and murne cell line RM-S have profound defects
in MHC class I antigen presentation (50 51), and only efficiently present peptides that are
targeted to the ER though signal sequences (52). Similarly, in TAP-deficient mice, stable
MHC class I molecule assembly is defective and cell surace MHC class I levels are
markedly reduced due to loss of peptide supply from the cytoplasm (53-55).
TAP is an ER membrane-integral heterodimer. Both of its subunits
, TAP- l and TAP-
are encoded by genes in the MHC class II locus
, closely lined to the LMP2 and LMP7
genes (56, 57). They are ATP-binding cassette (ABC) transporters capable of trans locating
peptides from the cytosol to in the lumen of the ER
, where MHC class I molecules are
waiting. Human TAPI and TAP2 exhibit 64% homology at the protein level
, and they have
a similar predicted membrane topology. There are eight and seven transmembrane (TM)
segments for TAP I and TAP2, respectively. TAPI has both its Nand C terminus in the
cytoplasm, whereas TAP2 has its N termus in the lumen of the ER. TAP is composed of
three sub-domains: a TM pore , a cytoplasmic peptide-binding pocket, and a nucleotide-
binding domain (ND) (58)
Peptide transportation by TAP involves several steps. The fIrst step is peptide binding
to TAP , which is an A TP-dependent process. Peptide binding causes topological changes in
the TAP complex, which trgger A TP hydrolysis and peptide translocation across the
membrane (59, 60). Recently, Cresswell and his colleagues found that ATP hydrolysis by
TAP2 , but not TAP 1 , is needed for both peptide binding and transportation (61). As with
many other components of the MHC class I antigen presentation machiery, TAP
expression is induced by IFy.
Several studies have characterized the substrate specificities of TAP (62
, 63). Based on
peptide trapping experients, random peptide mitues of 9-16 amio acids displayed
signficantly higher affinity for the bindig site than mitures of shorter or longer peptides
(59). TAP also has sequence preferences. The N-termal thee positions and the C-terminal
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residue are much more critical than other peptide positions (64). Mouse TAP has a strong
preference for peptides with hydrophobic C-termnal amio acids , while human TAP also
binds peptides with basic C-termini (65 , 66), which in each case correlates with the
preference of the MHC molecules of each species. This also correlates with the 
kids of
peptides generated by imunoproteasomes (see above). TAP polymorphism does not
measurably alter its specificity for peptide substrates (67).
1.6 Missing steps between peptide generation and TAP transporttion.
Present data show that proteasomes in the cytoplasm generate short peptides that are
transported by TAP into the lumen of the ER
, where the transported peptides bind to empty
MHC class I molecules. Are there any missing steps between proteasome and 
TAP? One
remaing question is how proteasome-generated peptides reach TAP molecules. It has
been proposed that proteasomes sit on the outer membrane of the ER
, so that peptides can
be transported into ER by TAP as soon as the peptides are generated
, or that there are carer
molecules that help to transport peptides to TAP.
One possibility is that, for effcient peptide binding to MHC class I molecules
, there is a
physical association between imunoproteasomes
, TAP1I2 complexes and MHC class I
molecules (68). If so, the MHC class I protein processing and presentation machinery could
be reguated not only by the level of expression of its components, but also by their
localization within the cell in ways that facilitate peptide binding and MHC class I antigen
presentation. If ths suggestion is correct, then if the proteasome or imunoproteasome
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generates a longer than authentic MHC class I bindig peptide, it would be imediately
transported into the ER, bypassing the cytosol. Consequently cytosolic enzes would not
play any role in trmming or degradation of epitopes. Since cytoplasmic aminopeptidases
such as leucine aminopeptidase
, puromycin-sensitive aminopeptidase and bleomycin
hydrolase, have been shown to be involved in MHC class I antigen presentation (48
, 49),
this model is probably incorrect. Also
, overexpression of a cytoplasmic endopeptidase
thimet oligopeptidase (TOP), strongly decreases MHC class I antigen presentation (69),
showing that peptides are accessible to cytosolic enzes.,
Another possibility is that there are carrer proteins between proteasomes and
TAPl/TAP2 complexes. It has long been proposed that peptides exist in the cytosol and ER
in association with heat shock proteins (70). HSPs are now known to play diverse roles
even in unstressed cells, in protein folding, assembly, intracellular localization
, secretion
reguation, and degradation of other proteins (71-73). HSPs may also play some roles in
immune response (74), especially in anti-tuor imune response (75-78).
Indeed it has been found that HSPs
, such as HSP70 molecules and the ER-resident
glucose-regulated protein 94 (gr94) bind peptides in vivo, though their role in MHC class I
antigen presentation is not clear. Injection of HSP-bound peptides into animals has been
found to elicit CTL responses to the bound peptides (79
80). After conditional
overexpression ofHSP70in a human melanoma cell line, Dressel et al. found that HSP70
does not affectMHC class I cell surace expression but did increase killing by CTL (81),
suggesting that HSP70 may facilitate transportation and presentation of 
certin peptides.
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Using a novel assay, Shastr' s group recently found that N-terminally extended
antigenic analogs were associated with high-molecular weight (30-0 kDa) material in the
cytosol before transport into ER through TAP (82). It is not known what these molecules
are , and more defInitive studies need to be done
, but this fmdig again raises the possibility
that cariers may exist between peptides generated by the proteasome and transportation by
TAP. Recently, Neefje s group found chromatiistones can bind peptides and protect
them from degradation (83).
Another HSP , the 27 -kDa heat shock protein (HSP27), which is expressed in a variety
of tissues in the absence of stress, is a potentially signficant effector protein that may
regulate actin dynamics , possibly by a phosphorylation/dephosphorylation mechanism (84).
HSP27 is involved not only in apoptosis, such as vis-induced cell death (85), but also in
cell surival, such as injured sensory and motor neuron surval and TN-mediated
apoptosis (86, 87). Human HSP27 is a potent inducer of IL- l 0 in human monocytes
suggesting that it may have a role in imune response (88). It has not been reported that
HSP27 is involved in MHC class I antigen presentation
, however, I wil show some data, in
which altering its expression can influenceMHC class I antigen presentation.
Aminopeptidases may tr longer peptides to the correct size in ER lumen
Proteasomes generate N-extended precursors of antigenic peptides that can be trmmed
by aminopeptidases to the correct size for presentation. It has been shown that longer
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peptides could be tred by aminopeptidases in the ER, as well as in the cytosol (89). 
has been demonstrated that an ER aminopeptidase tenned ERA 1 or ERA is at least one
of these ER aminopeptidases, for ifERAI is knocked out, the presentation of some longer
ER peptides is inhbited (1, 91).
1.8. ER chaperones facilitate MHC class I complex assembly
To ensure that only peptide-loaded MHC class I complexes are transported to the cell
surace, empty MHC class I complexes may be retained in the ER by a set of ER resident
chaperones, including calnexin and calreticulin (92), and ERp57 (93). The ER chaperones
help to control the quality of the exported MHC class I molecules by helping MHC class I
proper folding and assembly. The unloaded or misfolded MHC class I molecules are
transported to the cytosol, where they are degraded by proteasomes (94).
Calnexin associates with newly synthesized free MHC class I heavy chains and
, in
mouse but not human cells, newly assembled class I heavy chain- mdimers (95 96).
Calreticulin binds MHC molecules later than cahiexin
, and remains associated with
assembled MHC class I molecules (97) until the complex binds peptides and is transported
otit of the ER. Both calnexi and calreticulin interact with MHC molecules by binding
monoglucosylated N-linked glycans.
Another important ER protein involved in MHC class I antigen presentation is tapasin
which is a transmembrane protein that tethers empty MHC class I molecules to TAP
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complexes (98 , 99) and also enhances peptide loading ofMHC class I complexes in some
other way. Tapasin retains MHC class I molecules in the ER until they acquie high-affinity
peptides. Tapasin knockout mice show reduced MHC class I antigen presentation
, a skewed
repertoire of peptides displayed on the cell surface
, and a poor antiviral immune response
(100, 101).
Yet another MHC class I associated protein in the ER is ERp57
, a thiol oxidoreductase.
It may be involved in disulfide bond isomerization ofMHC class I molecules in peptide
loading (102). Since no ERp57 knockout mice are available now, it is not known whether
ERp57 is critical for MHC class I antigen presentation. Our lab has used siRA 
eliminate ERp57 in several cell lines
, but we did not find a significant reduction in MHC
class I antigen presentation (LA.York et aI. , unpublished data).
1.9. Some pathogens can evade the MHC class I antigen presentation pathway
MHC class I antigen presentation is a complicated pathway, involving many
components and steps. Many virses
, including herpesvirses , HIV, and adenovirs, have
been found to evade immune response by blockig MHC class I antigen presentation (103-
109). Many steps in the class I pathway can be inhibited by viral proteins after infection.
For example, herpes simplex virs ICP47 protein inhbits MHC class I antigen presentation
by binding to the TAP complex in ways that block peptide transport (110
, 111). Studying
viral imune evasion may provide us with more insights into MHC class I antigen
presentation.
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2 . Ubiquitin-conjugating enzes are involved in protein degradation
In the last three decades, it has been found that, under most conditions, the ubiquitin-
proteasome pathway is responsible for the lion s share of selective degradation of cellular
proteins (112). Ubiquitin is a small 76 amino acid protein with many roles in vivo.
Monoubiquitination is found to fuction as a signal in activities ranging from endocytosis
(113 , 114) to transcription regulation (115), which wil not be discussed in this introduction.
Polyubiquitination is used by cells to taget proteins for degradation by the proteasome.
In the process of polyubiquitination, there is a series of thee kids of enzes
involved: ubiquiti-activating enze (EI), ubiquitin-conjugating enze (E2) and
ubiquitin protein ligase (E3). In this process
, with ATP providig energy, ubiquitin binds to
a cysteine residue on Elvia a thioester bond. Ths activated ubiquitin is then transferred to
a cysteine residue on one of the many E2 molecules. In the presence 
ofE3 molecules, E2
molecules transfer ubiquiti to the e-amio group on lysines of target protein, forming an
isopeptide bond. By repeating this process fuer ubiquitin molecules wil be transferred
to the e-amo group of lysine of the existing ubiquitin, generatig polyubiquitinated
proteins (6).
Although there is only one El molecule in mamalian cells, more than 20 E2 have
been found so far (116). It is believed that anyone ofE2s may serve several E3s. The
different combinations of E2 and E3 molecules may target ubiquitin to specific proteins for
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degradation. In most cases , E3s may be regulated or modified by additional molecules
which may confine' the specificity of the target proteins (117
, 118).
Recently, it was found that polyubiquitination was involved in not only in the
destrction of soluble cellular proteins, but also in degradation of membrane-bound
, proteins. Indeed, ER proteins have been found to be transported to the cytosol to be
degraded (119-121). This may also contrbute peptide supply for MHC class I antigen
presentation, especially ofER-targeted proteins (121 , 122). Retrotranslocation of proteins
from the ER to the cytosol requires energy, perhaps because ubiqutination and/or the
proteasome is involved.
There are many excellent papers that review the ubiquitin-proteasome system (112
116). Here, I wil discuss the fuction of one of the E2 molecules, UBC9 , which is not
involved in protein degradation, but which may modify the fuction of taget proteins.
Ubiquitin conjugatig enze (Uc) 
UBC9 is an E2-1ike molecule
UBC9 was fIrst found in yeast as a nuclear protein involved in cyclin degradation
(123). Mutation of yeast UBC9 prevented cell cycle progression at G or early M phases.
Shortly thereafter, UBC9 homologues were cloned from human cells and mouse cells (they
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are identical at protein level (124, 125)), and were found to be associated with several
nuclear proteins such as RA51 , p53 , cyclin (126).
Many studies have attempted to elucidate the fuction ofUBC9 , and its exact roles and
mechanisms of action are stil not well understood. It has been observed to have many
different effects in cells. A limited number of studies have found a role in protein
degradation. Haber and his collaborators found that UBC9 was involved in the degradation
ofE2A, a helix-loop-helix protein involved in cellular growt and differentiation(127, 128).
Tashiro et aL found that UBC9 was directly involved in proteasome-dependent proteolysis
ofI-KBa (129). Therefore, it was proposed that, as with other UBCs, UBC9 is involved in
the polyubiquitination and proteasome-dependent degradation of these nuclear proteins.
However, shortly thereafter, it was found that UBC9 does not conjugate ubiquitin to target
proteins. Rather, it conjugates SUMO- l ( mall-!!biquitin-related difier) (130)) to
substrates (131 , 132), suggesting that UBC9 may be not involved in ubiquitin-mediated
proteasome-dependent protein degradation. In fact fuer studies, described below suggest
that UBC9 generally does not playa role in protein degradation.
SUMO- l has many different names such as PICI (133), sentr (134), GMPI (135),
UbIl (136), Smt3c (137), and hSmt3(138), for it was found by different groups with a few
months in S. cerevisiae, and mice, and human, respectively. As well, two related proteins
SUMO-2/SMT3A (139) and SUMO-3/SMT3B (137) have been characterized
, and are also
conjugated to taget proteins by UBC9 (140).
Although SUMO- l and ubiquitin have very similar strctues (141), they share only
18% amino acid sequence identity. The fIrst protein found to be conjugated to SUMO-
was Ran GTPase-activating protein (RanGAPl) (130). It was also found that UBC9 is
required for SUMO- l modification of RanG API (142- 144). Mammalian RanGAPI is
concentrated at the cytoplasmic face of the nuclear pore complex (NC), and is involved in
nuclear protein import. Interestingly, only SUMO- I-conjugated RanGAPl is associated
with the nuclear protein RanBP2
, which is involved in protein import
, suggesting that
sumoylation may be importnt in nuclear protein translocation. In mitosis
, SUMO-
conjugation is required for RanGAPI to associate with the mitotic spindle
, suggesting that
sumoylation plays an important role in spatial regulation of the Ran pathway during mitosis
(145). Also, sumoylation with SUMO- 1 re-localized Homeodomain-interacting protein
kinase 2 (IDPK2) to nuclear speckles (146). These results suggest that UBC9 may be not
involved in protein degradation, but may instead modify the fuction or localization of its
substrate proteins.
Another fuction of UBC9 is to regulate the activity of transcription factors. Since
UBC9 is a nuclear protein, it is not surrising that it can modify transcription factors. A
sumoylation motif can be found in many steroid receptors
, suggesting that UBC9 might play
a role in the reguation of transcription. In paricular, UBC9 interacts with the androgen
receptor (AR), a member of the steroid receptor famly, and activates receptor-dependent
transcription (147), and AR can be covalently modified by SUMO- l in an androgen-
enhanced fashion (148). Another well-studied transcription factor modified by UBC9 and
SUMO- 1 is p53. p53 trans-activation ability is increased by SUMO- l modification (149
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150). Sumoylation does not cause p53 degradation
, but inbits the degradative pathway
and increases the activity ofp53 as a consequence. The sumoylation site on p53 is K386
which is not utilized by ubiquitin. UBC9 has been found to increase the activity ofNF-
by associating with its upstream regulating protein MEKKI and the 
tye I TN-alpha
receptor (151) and by degrading I-KBa, which is a NF-KB inbitor (129). Other nuclear
factors modified by SUMO- l include Mdm (152, 153), C-Jun (154), topoisomerase (155-
157), AP2 (158), and many other transcription factors (159).
In fact, UBC9 does not only regulate the activity of nuclear factors. UBC9 also binds
glucose transporter GLUTI and GLUT4 and reguates their function (160). When UBC9 is
over-expressed in L6 skeletal muscle cells
, the basal glucose transport by GLUTI
transporter decreased 65%. By contrast
, GLUT4 transport is increased about 8 times
leading to enhanced transport stimulation by insulin. The 
mechansm by which UBC9
regulates GLUTI and GLUT4 is not known yet.
Although it has been reported that that UBC9 is involved in protein polyubiquitination
and degradatio, e.g. for I-KBa and E2A
, (127- 129), this may be not in fact be valid or
generally tre. Hay and his colleagues found that UBC9 conjugates SUMO- l to I-KBa, and
the sumoylated I-KBa is resistant to proteolysis (161). This is consistent with the 
fiding
that UBC9 conjugates SUMO- l but not ubiquiti to target proteins. UBC9 was also found to
conjugate SUMO- l to K21 of I -KBa, which is also utilized for ubiquitin modification.
Unlike polyubiquitination ofI-KBa
, which is phosphorylation-dependent, phosphorylation
ofS32 and S36 ofI-KBa inibits SUMO- l modification (161 , 162). In this case, it seems
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that sumo blocks the ubiquitination site and thereby prevents polyubiquitination and
degradation. Another HLH transcription factor
, TEL, was modified by SUMO- l (163), and
also interacts with UBC9 through its HLH domain
, but this interaction did not lead TEL
degradation (164). Whether E2A is lie I-KBa, in which ubiquitin and sumo utilize the
same motifs , should be fuer explored.
2. Sumoylation is an enzatic process very similar to ubiquitination
SUMO- l is conjugated to target substrates by a mechanism similar to ubiquitin. 
The
SUMO- l activating enze contains two subunits
, SAEl/SAE2 (165). In vitro
, in the
presence of A TP and recombinant SAE l/SAE2
, a thioester linage can be generated
between SUMO- l and SAE2. IfUBC9 is present
, SUMO- l is transferred to UBC9 from
SAE2. When the SUMO- l substrate I-KBa is added
, SUMO- l was efficiently transferred to
I-KBa from UBC9. SUMO-2 and SUMO-3 also use SAEl/SAE2 for sumoylation in vitro
(140). As with some ubiquitin-conjugating enzes
, UBC9 can diectly sumoylate,
substrates in vitro without the help ofE3-1ike enzes. However, due to the huge varety of
proteins in cells, and the specificity of sumoylation
, it is very unlikely that UBC9 conjugates
SUMO- l molecules to substrates without the help ofE3-
lie molecules.
Recently, E3-1ike molecules have been described in the 
sumoylation pathway. The first
E3-1ike molecules, Sizl and Siz2 , were found in S. cerevisiae (166
, 167). It was found that
these two molecules were requied in most known SUMO- l conjugations in yeast.
However, it seems unlikely that UBC9 and Sizl/Siz2 can specifically promote SUMO
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conjugation into many substrates
, although the authors argued that Sizl/Siz2 promoted
SUMO conjugation to different substrates at different stages of the cell cycle. Many SUMO
E3-1ike molecule have been found in mammalian cells
, including PIASI (159 , 168), PIASy
(169), RanBP2 (170, 171).
Additional molecules, such as E4, may help to provide specificity to the conjugation of
ubiquitin to substrates (117). Since sumoylation is 
so similar to polyubiquitination
, it would
be not surrising ifE4-1ike molecules are found in the futue to paricipate in sumoylation.
In mammalian cells, there are at least thee SUMO-like molecules: SUMO-
, and two
highly homologue molecules
, SUMO-2 and SUMO-3. Although it has been found that
SUMO-2 and 3 were more abundant than SUMO- l in COS cells (172), their functions are
less studied. Under normal conditions
, most SUMO-2 and SUMO-3 molecules exist in the
free form. Interestingly, SUMO-2/3 were conjugated to high-molecular-mass proteins when
the cells were subjected to protein-damaging stimuli. Also
, it seems that SUMO-2 and 3 do
not conjugate to SUMO- l substrates, such as RanGAPI. SUMO-2 and 3 also differ from
SUMO- l in that they can form polymeric chains in the absence of substrate in vitro
, while
SUMO- l can only form monomers on its substrates. However
, it is not known whether
SUMO-2 and 3 polymeric chains are formed in vivo. In fact
, it is unown how
physiologically importnt SUMO-2 and 3 are in vivo. Nevertheless
, these results suggest
that SUMO-2 and 3 have different fuctions from SUMO-
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An interesting finding is that mutation of the conserved active amio acid Cys to Ser
(C93S) ofUBC9 , which prevents sumoylation by disrupting the formation of a thiolester
bond between SUMO- l and UBC9, blocks UBC9' s sumolylating activity but has no effect
on its fuction in stimulating AR-dependent transactivation. This may suggest that UBC9
can act as an AR coreguator independent of sumoylation. AR is not exceptional in its being
affected by mutant UBC9. Many papers have showed that mutation of Cys 93 in UBC9
does not affect its interaction with substrate proteins (164
, 173 , 174), even though most of
the interacting proteins are SUMO- 1 substrates (163). How does mutant UBC9 regulate
substrate protein fuctions? One explanation is that UBC9 can reguate the fuction of its
substrates by direct binding in the absence of SUMO molecules. Another possibility is that
since most of these studies have been done by overexpressing mutat UBC9 in cells that
constitutively express wild tye UBC9, the mutant UBC9 might modify the fuction of its
substrates by binding to a previously conjugated SUMO molecule. In other words
, in ths
model mutant UBC9 binds to its substrates only after endogenous (non-mutated) UBC9 has
conjugated SUMO to target proteins.
4. Object of this project
UBC9 is involved in MHC class I antigen presentation
In our study of how different UBC molecules regulated protein degradation and MHC
class I antigen presentation, we found that UBC9 overexpression increased Kb-SIINEKL
level on COS-Kb cell surface when ovalbum is used as model protein. The goal of ths
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thesis was to investigate the basis for this effect and to elucidate the potential role ofUBC9
in antigen presentation.
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CHATER II MATERILS AN METHODS
Cell lines
Cell lines used in this experiment include COS-7 cells (Afrcan Green Monkey kidney
cells) (175); COS- (H- transfected COS-7 cell line) (1, 91); Hela (176, 177); Hela-
(H- transfected Hela cell line) (1, 91) and E36- cell (E36. 12.4) (E36 transfected with
and ICAM) (47). COS-7 cells were grown in complete RPMI1640 medium
(RPMI1640 medium supplemented with 10% Fetal Bovine Serum (FBS), L-Glutamie
penicilin (100U/ml), streptomycin (100U/ml)). COS-
and E36- cell lines were
maintained in complete RPMI1640 medium supplemented with G418 (250 g/ml). Hela
cells were maintained in complete DMEM medium (DMEM medium supplemented with
10% FBS L-Glutamine, penicilin (100U/ml), streptomycin (100U/ml)). Hela- cells were
maintained in complete DMEM medium supplemented with G418 (250
glml).
Antibodies
The H- SIINEKL specific antibody 25.D1.16 (178) was kidly provided by Dr. R.
Germain (N, Bethesda, MD). W6/32 (179) is specific for HLA-
, B , C; Y3 (180) is
specific for H- 12CA5 recognzes the HA tag (181
, 182). Rabbit anti-MECL1 , anti-
LMP2, and anti-LMP7 (183- 185), were kindly provided by Dr. A.L. Goldberg, Harard
Medical School, and anti-PA28a andanti-PA2813 (186) were kidly provided by Dr. George
DeMartino (University of Texas Southwestern Medical Center
, Texas). Anti-UBC9
monoclonal antibody was purchased from BD Phargen (San Diego, CA). Rabbit anti-
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ovalbumn serum was purchased from ICN (Costa Mesa
, CA). Rabbit anti-HsplO5 was
purchased from Santa Cruz biotech (Santa Cruz
, CA). Anti-Flag monoclonal antibody M2
was purchased from Sigma (St. Louis
, MO). Anti-Xpress antibody was purchased from
Invitrogen (Carlsbad
, CA). Anti-TAPI and anti-Tapasin antibodies were kidly provided by
Dr. Peter Cresswell (Yale University, New Haven
, CT) or purchased from Stressgen
(Victoria, BC, Canada) or Calbiochem (San, Diego
, CA). Rabbit anti-calreticulin and anti-
calnexin, and anti-HSP27 monoclonal antibody was purchased from Stressgen. Rabbit anti-
ORPl50 (187) was kidly provided by M. Matsumoto (Osaka University Medical School
Suita City, Japan). HLA-A heavy chain specific mA HCA2 and HLA- C specific 
antibody HCI0 (188) were kindly provided by H. Ploegh 
(Harard Medical School).
Proteins and peptides
Ovalbumin (grade VI) was purchased from Sigma. All peptides used in the
experients were synthesized by Corixa corporation (Seattle
, W A). Lyophilized peptides
were reconstituted in DMSO at a concentration of 10m and stored at -
Reverse transcriptase PCR (RT-PCR)
COS- cells (50%-75% confluent in 75 cm2 plates) were 
trsinzed and washed with
PBS three times. mRA was extracted using with an RNeasy kit (Qiagen
, Valencia, CA)
according to the manufactuer s protocol. A cDNA pool was generated from COS-
mRA using SuperScript II RNase H- Reverse transcriptase kit (Invitrogen) according to
the manufactuer s protocol.PCR using this cDNA as template was performed using
Platium Pfx DNA Polymerase kit (Invitrogen) according to the manufactuer
s protocol.
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Plasmid vectors
Both pTracer-CMV (Invitrogen) and pTre2 vector (Invitrogen) were kindly provided by
Dr. E.J. Luna. pTracer-CMV2, pcDNA3.1 , pcDNA3. 1/His A, B , C were purchased from
Invitrogen (Carlsbad, California), pTet-ON plasmid and pBI-EGFP were purchased from
Clontech (Palo Alto
, CA) .
Expression plasmids
pTracer-CMV-UBC9: pCR3. UBC9 (128) was kidly provided by Dr. Mu-En Lee
(Harard School of Public Health). To add a flag tag to the N-termus ofUBC9, UBC9
was amplified with: Forward Primer (with EcoRI 
site): 5'
GAATTCCATGTCGGGGATTGCCCTCAGC- ; Reverse Prier (with KpnI site): 5'
GGT ACCAA TCCCTTCCTCGTCA TG-
. The PCR product was digested with EcoRI
and KpnI, and ligated to pCMV2 vector
, which had a FLAG tag (kdly provided by
Vincent Chau, Pennsylvana State University)). Flag-UBC9 was then amplified with
forward primer (witb KpnI): 5' GGTACCGTCAGAATTGATCTAC-
, Reverse Prier
(with KpnI): 5' GGTACCAATCCCTTCCTCGTCATG-
. The PCR product was
digested with KpnI and ligated to KpnI digested pTracer-CMV-Vector. The insert direction
was confIrmed by enze digestion and DNA sequencing.
Mutant UBC9, in which the active cysteine has been changed to serie
, was made by
site-directed point mutation approach based on the protocol described by LJ Zhao (189), in
which a mismatched oligonucleotide is extended
, incorporating the "mutation" into a strand
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of DNA that can be cloned. For makg UBC90H (in which the active amno acid cysteine
93 ofUBC9 was mutated to serie), the inside priers were 5'
CAGGATGGACAGGGACACTGTGCCAG-3' (prier 2) and 5'
TCTGGCACAGTGTCCCTGTCCATCCTG-3' (primer 3).
A plasmid containing SUMO- l (131) was kidly provided by R.T. Hay (University of
St Andrews, St Andrews, UK); Ube2G2 (190) was kidly provided by S.A. Rose
(University of Leeds, UK); and ubiquiti (191) was provided by R.R. Kopito (Stanford
University, Stanford, Californa),
All other genes were cloned from a COS-7 cDNA pool by PCR amplification. The
following is a list of priers used for makg wild tye and mutant plasmids of each gene:
Table 1
Gene name Priers Sequence (5' NoteUBC9 Prier 1 CGGAATTCCA TGTCGGGGA TTGCCCTCAGC Underlied is EcoR! sitePrimer 4 GGGGT ACCAA TCCCTTCCTCGTCATG KnnIUBC90H Prmer 2 CAGGATGGACAGGACACTGTGCCAG For makg mutat genePrimer 3 TCTGGACAGTGTCCCTGTCCATCCTG
nrier 1 and 4 are usedpTracerHA- Primer 1 AAACTGCAGTGTCTGACCAGGAGGCAACC
Pst I SUMO- Primer 4 CGCTCTAGACTAACTGTTGAATGACC XbaI
pTracerHA- Primer 4 CGCTCTAGA TCACGTTGTTCCTGATAACTC XbaISUMO- I (rout) (mut)
pTracerHA- Prier 1 GCGGAATTCCA TGTCCGAGGAGAAGCCCAAGG EcoR 1. Prier 4 ha noSUMO- Prmer 4 TCATCGTGGTGAATGTCCTCG cuttng site. But there is a
XbaI with the product,
afer the stop codonpTracerHA- Primer 2 CTCCGGCACAGCTGCCGTCTGCTG Two GG active aa haveSUMO-2 (rout) Primer 3 CAGCAGACGGCAGCTGTGCCGGAG been changed to AA
pTracerHA- Primer 1 GCGGAATTCCATGGCCGACGAAAAGCCCAAGG EcoR ISUMO- Prmer 4 GGCTCT AGATCAGTAGACACCTCCCGTCTG XbaI
pTracerHA- Primer 4 GGCTCT AGA TCAGTAGACAGCGCCGTCTGCTG XbaISUMO-3 (rout) (mut)
pTracer-CMV - Prier 1 TCAGAATTCCA TGACGGAGCTGCAGTCGGCAC EcoR!Ube2G 1 Prier 4 ATGCGGT ACCTCACTCAAGCAGTCTCTTGG KpnI
pTracer-CMV - Primer 2 GAAGAATAGAATGGACACATCACC C::SUbe2GIOH Prer 3 GGTGATGTGTCCA TTCTATTCTTC
pTracer-CMV- Prier 1 TAGAA TTCCATGGCGGGACCGCGCTC EcoR!
Ube2G2 Primer 4 GGGGT ACCTCACAGTCCCAGAGACTTCTGG
KpnIpTracer-CMV - Prmer 2 GGAGGATGGAATGGAGACTCTCCCATCAG
Ube2G20H Prier 3 GGGAGAGTCTCCATTCCATCCTCCAC
pTracer-CMV- Prier F GCAGGAA TTCATT ATGCAGATC
EcoRlUbiquitin Primer R GCGCGAATTCTCAACCACCTCTTAGTCTAAG EcoRl
pTracer-HA- Primer F T AGCGGAA TTCCAGCATGACCGAGCGCCGCGTC
EcoRlHSP27 Prier R T AGGCTCT AGACGGGCTAAGGCTT ACTTGGC XbaI
Other plasmids were constrcted using standard cloning techniques (192). All the
plasmid DNA sequences were confIrmed by sequencing (Nuclear Acids Facility, University
of Massachusetts Medical School
, Worcester, MA).
Table 2
3.1
Transfection:
Cells were transfected with Fugene 6 (Roche Applied Science
, Indianapolis
, IN
according to the manufactue
s instrctions. Briefly, the day before transfection
, cells were
plated on 6-well plates or 6-cm diameter tissue 
cultue dishes at 3x10 /well (for 6-well
plates) or 7x10 /dish (for 6-cm dishes). 24 hour later
, cells (at confuency of 50% - 70%)
were transfected with plasmid(s). The ratio ofFugene6: DNA was 3 
!-1:1 !-g. After
transfection, the cells were incubated at 37
, 5% CO for 20-48 hours. For co-transfection
plasmids were mixed fIrst
, and then mixed with FuGene 6.
Selecting low H- expressing COS- cells with MACS
Magnetic bead activated cell sorting (MCS) was done according to the manufactuer
protocol (Miltenyi Biotech, Aubur, CA). Briefly, COS- cells were trsinized and
washed 2 times with complete RPMI1640 medium
re-suspended in H-
-specific
monoclonal antibody Y3 supernatat (180), and incubated 
on ice for 15-20 miutes. After
two washes with cold PBS buffer supplemented with 5% FBS (pBS/FBS), the cells were re-
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suspended with goat anti-mouse IgG magnetic beads (Miltenyi Biotech
, Aubur, CA)
(1 : 100 - I: 150 diluted in PBSIFBS), and incubated on ice for a fuher 15 minutes.
Negative selection was done with MACS separation colum (LS or CS). The flow through
(low H- -expressing) cells were collected and grown in G418-free complete RPMI1640
medium.
Generating ovalbum stable transfectants
To generate stable transfectants
, COS- cells were transfected with pcDNA3. 1/Hygro-
CD- 16-0V A, pcDNA3. 1/Hygro-N50-0V A, or pcDNA3. 1/Hygro-minigene. Twenty-four
hours after transfection, the cells were trsinized and seeded in medium containing 300
!-glml hygromycin in new dishes. Two days later, the medium was changed, the cells were
grown in the presence ofhygromycin for 3 more days , and then limt-diluted into 96-well
plates. Single colonies were selected and expanded in 24-well plates and then in 6-well
plates. Cells stainng with 26.D1.16 (anti-SIINEKL+H- ) were used for studying UBC9
fuction in MHC class I antigen presentation.
Antibody staing and F ACS analysis
Cells were trysinized and washed with complete RPMI1640 medium twice
, re-
suspended in 100 !-l antibody supernantant and incubated on ice for 45 minutes. After two
washes with cold PBS buffer supplemented with 5% FBS
, the cells were re-suspended with
Cy5-conjugated goat anti-mouse IgG antibodies or PE-conjugated donkey anti mouse IgG
antibodies (Jackson ImunoResearch Laboratories
, West Grove, PA) (1:100 
- 1:150 diluted
in PBSIFBS), and incubated on ice for a fuer 45 miutes. The cells were then washed
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with cold PBS 2 times and examined on a F ACSCalibur apparatus (Becton Dickison
, San
Jose, CA) using CELLQUEST softare (Becton- Dickison) and analyzed with Flowjo
softare (Tree Star, Inc. San Carlos, CA). When cells were transfected with GFP-
expressing plasmids, such as pTracer-CMV, analysis was restrcted to GFP-positive cells.
Inducible ovalbumin expression
Cos- cells were co-transfected with pTet-ON-Vector or pTet-ON-UBC9, and pBI-
EGFP-CDI6-0V A, pBI-EGFP-N50-0va, pBI-EGFP-ES-Mingene or pBI-EGFP-Minigene.
Twenty-four hours after transfection
, the cells were trsinized and washed with RPMI1640
(seru-free) 2 times. To remove any preexisting peptide-MHC complexes, cells were acid-
washed with 1 ml acid washig buffer (1:1 mixtue ofO. 163M citric acid and 0.32M
NaH2 ) for less than 1 miute. The acid buffer was neutralized with 10ml cold Na2HP0
buffer (1 M, pH7.5). The cells were washed with cold Opti-MEM 2 more ties and grown
in RPMI1640 complete medium containng doxycycline (20 
g/ml) at 37 C and analyzed
for the presence of peptide-MHC complexes by flow cytometr at different time points.
Protein or peptide loading experiments with hypertonic solution
Cos- cells were transfected with pTracer-CMV-vector or expression plasmids.
Twenty eight hours after transfection
, the cells were trsinzed
, washed 3 times with
seru-free RPMI1640 medium and transferred to a 14 ml tube. Angen was loaded into the
cytosol by hypertonic lysis of pinosomes. The cells were re-suspended in 200 lloadig
buffer (described in appendix) containg ovalbumin (80 mg/ml) or peptides (0.2mg/ml for
N5-SIINEKL
, O. lmg/ml for STIEKL
, O.5mg/ml for STIEKLT). After incubatig in a
C water-bath for 10 minutes, 2.5ml pre-wared hypotonic solution (described in
appendix) was added, mied, and the cells were incubated at 37 C for 3 miutes. The cells
were spun down and washed with ice-cold SF-Opti-Mem (see Appendix I) medium four
times to remove excess antigen. For peptide loadig, after one wash with ice-cold SF-Opti-
Mem medium, the cells were acid-washed once and then washed with ice-cold SF-Opti-
Mem medium twice (193 , 194). The cells were re-suspended in complete RPMI1640
medium and grown at 37 C in 5% incubator. At varous time points
, cells were analyzed by
flow cytometr.
Peptide protection experients: Antigen presentation assay
Cos-7 cells were plated in 15-cm diameter dishes (3xl0 cells/dish). Twenty-four hours
later, the cells were transfected with pTracer-CMV -vector or pTracer-CMV -UBC9 plasmid
(25 g DNA and 75 1 Fugene6 per dish). Twenty-eight hours after transfection
, the cells
were loaded with SIINEKL peptide (0.5mglml) with hypertonic solution (appendix), and
washed 3 times with seru-free RPMI 1640 medium. The cells were re-suspended in
complete RPMI1640 medium
, and grown at 37 oc. At varous times cells were lysed with
10% TCA or TF A and boiled for 15 miutes
, and then incubated on ice for 10 minutes. The
celllysates were neutralized with NaOH
, centrfuged at 14 000 rpm for 10 mi, and the
supernatant (peptide extract) was transferred to another eppendorftube. Ths peptide extract
was then assayed for the presence of STIEKL with a T cell hybridoma assay.
The peptide extract was titered in 2-fold dilutions across a 96-well plate (Cornng-
Costar, Acton, MA) (50 l/well), and fIxed E36-Kb and RF33.70 cells were added at
100 l/well (1 x 10 cells/well) and incubated 18-24 hrs at 37 C in 5% CO . To fix theE36-
Kb cells , they were washed 3 times with PBS and fixed with 1 % paraformaldehyde in PBS
for 15 miutes at room temperatue. The cells were washed with two volumes ofRPMI
1640 thee times. RF33.70 cells (specific for SIINEKL complexed withH- ) were
washed twice with RPMI1640fFCS medium and resuspended with the fixed E36-Kb cells in
hybridoma cultue medium (HCM) at I x 10
cells/ml each. One hundred l supernatant was
frozen at - C overnight and used in an IL-2 assay.
IL-2 assays were performed as described in (47). Briefly, CTLL-2 cells were washed
thee times with RPMI1640+5% FCS
, resuspended at 2xlO /ml in HCM with an equal
volume of nutrtional cocktail (50 ml ofRPMI supplemented 
with 1 ml of dextrose (500
mglml stock in RPMIJ, 2 ml of essential amio acids, 1 m1 of non-essential amo acids, 1
ml ofL-glutamine, 1 ml ofpenicilin-streptomycin-fungione, and 50 ml ofFBS). This cell
suspension was added to wells at 5x10 cells/well. After 18-22 hours at 37 , 5% CO the
cells were pulsed with 3 thymdine media (1 mllmci/ml 3H thymdine in 24 ml HCM).
After 5 or 6 hours supernatant was harvested and incorporated 3H thymdine counts were
measured in a Microbeta liquid scintilation and Luminescence counter (PerkinElmer
Wallac Inc, Gaithersburg, MD)
Peptide protection experients - HPLC experients
COS-7 cells were grown to 50-70% confuency in 150 cm2 cultue plates and
transfected with pTracer-CMV - Vector or pTracer-CMV -UBC9. Twenty-eight hours after
transfection, the cells were placed on ice and cultue medium was discarded. Cells were
washed thee times with ice-cold PBS
, pH 7.4, and remaining PBS was removed. Cells
were covered with 1.5 ml of homogenization buffer (50 mM Hepes
, pH 7.4 adjusted with
KOH, 2 mM MgCh, 0.5 mM ATP, 1 mM DTT), and scraped off the plates into the buffer
with a cell lifter. This cell suspension was then used to harvest cells in the second plate
, and
so on until cells in all plates were harvested in 1.5 ml of the homogenization buffer.
Cell suspensions were transferred to a 7- 10 ml (or smaller) glass douncing homogenizer
on ice. After douncing about 40 times
, the homogenates were transfered to 1.5 ml
Eppendorftubes and centrfuged at 14 000 rpm for 10 mi at C in Eppendorf centrfuge to
remove nuclei, mitochondra, lysosomes and plasma membranes. The 
supernatats from the
fIrst spin were additionally centrfuged at 100 000xg for 2 hours. Protein concentration in
100 000xg supernatants was determned by the Bradford assay (Pierce
, Rockford, IL).
Samples were aliquoted into 100 Jll aliquots / 0.5 ml tube. Aliquots were snap-frozen in
liquid nitrogen, and kept at -
Five nmol of ESIINEKL peptide was incubated at 37 oC for varous time intervals
with 10 Jlg extracts from COS7 cells transfected with pTracer-CMV vector or pTracer-
CMV-UBC9 , in 100 Jll f50 mM Tris-HCl, pH 8. , 5 mM MgCh, 20 JlM MG132. The
reaction was termated by the addition of 100 Jll of 20% trcWoroacetic acid followed by a
15-mi incubation on ice and removal of the precipitated protein by centrfugation for
15 mi at 20 000 g. The peptide-containing supernatant was subjected to reverse-phase
HPLC on a 4.6 x 250-mm Vydac S-Jlm C18 colum (Vydac, Hesperia, CA) in 0.06%
trfluoroacetic acid with a flow rate of 1 ml/mi. Elution was performed with a 30-min linear
, " ' -
gradient from 5 to 60% acetonitrle. The amounts of eluting peptides were calculated by
integration of peptide peaks on chromatograms and are given in arbitrary 
unts (195).
Pulse-chase Imunoprecipitation
Cos-Kb cells were plated on 75 cm2 plates and transfected with expression plasmids.
Twenty-eight hours after transfection
, the transfected cells were 
trsinzed and washed for
2 times with labeling medium (methonie and cysteine-free RPMI1640 (Sigma)
supplemented with L-glutamie and 10% dialyzed FCS). Cells were resuspended with 2 ml
oflabeling medium
, and incubated at 37 Oc in 5% for 1 hour. Twenty-five J-l
250J-Ci) of esS) methionie/cysteine (EasyTag, Perkilmer Life Sciences Inc. , Boston
MA) was added per well and incubated for 5-20 miutes (Pse). The cells were washed
with non-radioactive complete medium 2 times
, and resuspended in 3.5 ml chasing medium
(RPMI1640 supplemented with 500 J-g/ml cysteine-HCl, 100J-g/ml methionine, sterile
filtered), and grown at 37 C in 5% CO
. Cell suspensions were taen at different time
points and washed 2 times with PBS. Cells were lysed with lysis buffer 
(1 % NP40 
150mM NaCl, 50mM Tris pH 8. , ImM EDTA) supplemented with complete protease
inbitors (EDT A free) (Roche) on ice for at least 
15 minutes. After centrfugation at
000 rpm for 10 minutes
, the supernatants were collected
, and subjected to
immunoprecipitation.
Protein A-agarose beads (Repligen
, Waltham, MA) were incubated with irelevant
antibody or with normal rabbit seru in lysis buffer for 1 hour at 4 oc. The beads were
washed briefly, resuspended with celllysates
, and incubated for 1 hour at 4 O
c to px:eclear
40...
the lysates. Protein A beads pre-incubated with specific antibody were added to the cleared
lysates and incubated for 2 hours at 4 oC. The beads were washed with lysis buffer 3 times
resuspended with Laemmi' s sample buffer, and heated to 100 Oc for 10 miutes. Samples
were separated by SDS-PAGE on 12% acrylamide, treated with Autofluor (National
Diagnostics , Atlanta, Georgia) for 30 miutes, dred, and exposed to X-ray film for
appropriate periods at -80 o
Protease inbition experients
Cos- cells were transfected with pTracer-CMV-vector orpTracer-CMV-UBC9.
Twenty-eight hours after transfection
, the cells were trisinized, washed 3 ties with
seru-free RPMI1640 medium and grown in medium containg protease inibitors for 1
hour. The inhibitors were: proteasome inbitor 13-1actone; inibitor ofthol proteases (such
as Cathepsin Band BH) E64; calpain and calpain II inbitor E-64C; serie protease
inbitor AA -CMK; leucine aminopeptidase inbitor bestatin; leupeptin, which inibits
chymotrsin, plasmi, papain and cathepsin B; chymostatin
, which inbitis chymotrsin
papain; and cathepsins A, B, and D inhbitor chymostatin. All inibitors were used at
100llM except for leupeptin, which was used at ImM. The cells were then hypotonically
loaded with ovalbum, incubated in inibitor-containg medium, and analyzed by flow
cytometr.
Fluorescent imunocytochemistr.
The day before transfection, Cos- cells were plated in 24 well plates on a cover glass.
Cells were transfected with pTracer-CMV -Vector or pTracer-CMV -UBC9 (Flag tagged),
pCMV2-UBC9 (wild tye) or pcDNA3. Twenty-eight hours after transfection, the cells
were fixed with dr-ice cold acetone/methanol (1:1) for 1 mi and air-dred for 10 miutes
rehydrated in PBS for at least 2 minutes, and blocked with blocking buffer (2% normal goat
serum in PBS), for 1 hour at room temperatue. Wells were drained completely. , Cells were
stained with 2501-1 priary antibody (I: 100 diluted in blockig buffer) for 45 miutes, and
then washed for 3 times with PBS , 10 miutes/time and stained with 2501-1 secondar
antibodies (rhodane-conjugated goat anti-rabbit IgG and FITC-conjugated goat anti-
mouse IgG, 1:100 diluted in blocking buffer) for 45 minutes and washed for 3 ties with
PBS , 10 minutes/time. Cells were stained with DAPI (4' diamidino- phenylindole
dihydrochloride hydrate, 1 I-g/ml) for 10-20 miutes, and washed twice with PBS , 10
minutes/time. Cover glasses were mounted onto slides with Fluoromount-
(Southernbiotech Inc. Birmngham, AL), dred overnght at room temperatue and stored at 
C until fluorescence microscope examination.
IFy and poly I:C treatment of COS cells and Dendrtic cells
To know whether IFy and IFa have effect on UBC9 expression, COS-Kb cells
bone marrow-derived priar mouse dendrtic cells, monocyte-derived human dendrtic
cells , or DC2.4 cells were grown in 6-well plates with FNy (250uml/well) (Biogen
Cambridge IFy, MA) or polyI:C (Sigma) ( 25 I-g/ml
, 51-g/ml, 2.5 I-glml, and 1 I-g/ml). The
cells were cells trsinied after 1 day, 2 days , and 3 days, and analyzed on western blots as
described below.
Polyacrylamde gel electrophoresis and imunoblotting
After cell lysis as described above 1/3 volume of 3X loading buffer (NB
, Beverly,
MA) and DTT (NEB) was added to the samples
, and they were then boiled for 5-
minutes. Samples were subjected to SDS-P AGE. Proteins were then transferred from the
gel to 0. m nitrocellulose membrane PROTRA (ScWeicher and Schuell, West Chester
P A) at 67V for 2.5 hours. The membranes were then removed from the transfer apparatus
and placed into blockig solution (5% fat-free milk in PBS with 0.2% Tween 20 (PBST))
overnight at room temperatue. The membranes were then incubated with priar antibody
diluted in blockig buffer as suggested in the product description sheet
, and incubated with
agitation for 1 hour at room temperatue
, washed for 30-60 minutes with agitation in PBST
buffer, changig the wash buffer every 10-15 miutes, and incubated with HR-conjugated
secondar antibody diluted in 5% non-fat dr milk in wash buffer (sodium azide-free) for 1
hour. The membranes were washed again for 30 minutes to 1 hour for monoclonal
antibodies, and at least 2 hours for rabbit polyc1onal antibodies. The blots were developed
using SuperSignal West Pi co Substrate (Pierce, Rockford, IL) for 5 minutes. The
membranes were dred by touchig against paper towers, wrapped with plastic wrap, and
exposed to X-ray film (Eastman Kodak Company, Rochester
, New York).
Small interferig RNA (siRNA) treatment
All siRA used in the experients was synthesized by Dharacon Research, Inc
(Lafayette, CO), and was anealed exactly as described (196). Double stranded RNA
specific for human UBC9 mRA are5' AUGUAAUUCGAACCACCAdTdT-3' (sense);
and 5' UGGUGGUUCGAAUUACAUdTdT-3' (complement). Double stranded RNA
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specific for human HSP27 mRA are 5' GUUCCUCCUCCCUGUCCCdTdT-3' (sense)
and 5' GGGACAGGGAGGAGGAACdTdT-3' (complement).
Cos- cells were grown in 6-well plates at 1.5xlO /well. Twenty four hours later the
cells were transfectecl with siRNA, using Transit TKO (Mirs, Madison, WI), followig the
protocol provided by the manufacturer. Briefly, Transit-TKO reagent (3 l) was added
dropwise into 50 l Opti-MEM, mixed thorougWy and incubated at room temperatue for 5
to 20 minutes. Five l of 20 M siRA was added to the diluted Transit-TKO reagent
mixed well and incubated at room temperatue for 5 to 20 minutes. The Transit-TKO/siRNA
mixtue was added dropwise into the cells, while swirling the plates. Cells were incubated
for 24, 48 , and 72, and 96 hours before analysis.
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CHATER III. RESULTS
1. UBC9 overexpression increases surace H- SIINEKL levels
To evaluate the effect ofUBC9 on antigen presentation, I co-transfected COS- cells
with pTracer-CMV-UBC9 , or pTracer-CMV vector, and pcDNA3. CDI6-0V A (which
targets the protein to ER) (see Table 2), and after 24 hours measured the levels ofH-
SIINEKL complexes at the cell surace with the H- SIINEKL complex-specific
monoclonal antibody 25.D1.16 (178). The pTracer-CMV vector co-expresses GFP , so
transfected (GFP+) cell populations were gated and analyzed in flow cytometr. pTracer-
CMV-UBC9 and pTracer-CMV-UBC90H plasmids expressed high levels ofUBC9 protein
in COS- cells (Fig lA). Compared to vector-transfected cells , those expressing UBC9
showed markedly increased expression ofH- SIINEKL complexes (Fig IB).
Interestingly, the mutant UBC90H, in which the catalytic cysteine 93 has been mutated to
serie and which should not be able to conjugate ubiquitin or sumo to substrates (157) , had
the same effect as its wild-tye counterpart in increasing H- SIINEKL level (Fig lC).
But ths effect is not due to UBC9 increasing protein synthesis, since both wild tye and
mutant UBC9 did not increase ovalbum and HLA-A3 protein protein levels (Fig ID, E).
These observations led us to study the role ofUBC9 in MHC class I antigen presentation. 
1. UBC9 overexpression increases surace H- expression
The amount of class I molecules expressed on the cell surace is strongly inuenced by
the supply of antigenic peptides in cells. To know whether UBC9 overexpression affected
MHC class I antigen presentation generally or was limited to SIINEKL or only a few other
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Fig 1. COS-Kb cells transfected with pTracer-CMV-UBC9 and pTracer-CMV-
UBC90H express high levels of UBC9 and increase surfaceH- SIINFEKL
levels without increasing protein synthesis. A. COS- cells were transfected with
vector, pTracer-CMV -FLAG-UBC9, or pTracer-CMV -FLAG-UBC9. Twenty-four
hours after transfection, the cells were lysed and a western blot was performed with
anti-UBC9 antibody. Band C. COS-Kb cells were co-transfected with ovalbumin
plasmid and pTracer-CMV-Vector, or pTracer-CMV-Ubc9 (B) or pTracer-CMV-
Ubc90H (C). Twenty-four hours after transfection, the cells were stained with H-2Kb-
SIINKL specific antibody 25..D1.16 and GFP+ populations were analyzed by flow
cytometry. E and F: COS- cells were co-transfected with pTracer-OV A and control
vector, Ubc9 , or Ubc90H (E); or COS- cells were co-transfected with pTracer-
HLA-A3 and control vector or Ubc9 (F). Western blot was done 24 hours after
transfection. Membranes were probed with anti-OVA and anti-A3 antibody (HCA2)
respectively.
epitopes , we transfected Cos- cells with pTracer-CMV -UBC9 and pTracer-CMV-
UBC90H and measured the effects on overall MHC class I expression on the cell surace.
We found that UBC9 overexpression has very little effect on endogenous MHC class I
antigen presentation (Fig 2A), and only slightly increased H- levels (Fig 2B), though the
effect was not as dramatic as the increase in K SIINEKL levels described above (section
1). Since these COS- cells express very high levels ofH- , it seemed possible that its
expression was already at a maximum and could not be fuher increased by enhancing
peptide supply. If so, the effect ofUBC9 on MHC class I antigen presentation (such as
peptide supply for H- ) might be difficult to detect.
To circumvent this potential limitation, we used the magnetic cell sorting (MACS)
technique to select COS-Kb clones that expressed low levels ofH- , followed by
limiting-dilution subcloning. We selected a clone that expressed low but easily-detectable
levels of H- on the cell surace. These cells were transfected with pTracer-CMV vector
pTracer-CMV-UBC9 or pTracer-CMV-UBC90H. Twenty-four hours after transfection, the
cells were stained with an anti-Kb antibody (Y3). In these H- low cells, UBC9 (Figue
3A) and UBC90H (Figue 3B) overexpression strongly increased H- level on cell
surace, suggesting that UBC9 has a general enhancing effect on MHC class I antigen
presentation.
1.2. UBC9 increases H- SIINEKL expression on cells transfected with all
forms of SIINEKL precursors
Endogenous MHC class I 2Kb
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Fig 2. UBC9 overexpression has little effect on surface endogenous
MHC class I levels. COS- cells were transfected with UBC9 or control
vector. Twenty-eight hours after transfection, the cells were staned with
HLA-A, B , C specific antibody W6/32 or H- specific antibody Y3 and
GFP positive cells were analyzed by flow cytometr.
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Fig 3: Ubc9 and mutat Ubc9 over-expression globaly increases MHC class I antigen
presentation. Low H-2Kb-expressing COS-Kb cells were transfected with pTracer-CMV
vector, pTracer-CMV-Ubc9, or pTracer-CMV-Ubc90H. Thir-six hours after transfection,
the cells were stained with H-2Kb-specific antibody Y3 and GFP+ cell populations were
analyzed by flow cytometr.
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MHC class I antigen processing and presentation follows a multi-step pathway
involving gene transcription, protein synthesis, antigen degradation, peptide trmming,
peptide transport, MHC complex assembly, peptide binding, and transport of complexes to
the cell surace as MHC class I-peptide complexes. My observations above showed that
UBC9 overexpression up-regulated MHC class I antigen presentation. To identify at which
step(s) UBC9 affects MHC class I antigen presentation, I used ovalbumin as a model
protein; different constrcts were used to test different steps in the pathway.
Because UBC9 has been implicated in altering the subcellular localization of proteins, I
initially tested whether UBC9 overexpression differentially affected ovalbumin targeted to
different regions of the cell. Cos- cells were co-transfected with UBC9 and 3. 1 (pCDL-
SRa296-CD 16-0V A-LAMP. 1) (which encodes endosome/lysosome-targeted ovalbumin),
pcDNA3. CD 16-0V A (which encodes ER lumen-targeted ovalbumin), or pcDNA3. N50-
OVA (which targets ovalbumin to the cytosol). We found that UBC9 overexpression
increased H- SIINEKL levels on Cos- cells transfected with all these forms of
ovalbumin (Figue 4A-D). The largest increases were found on cells transfected with ER-
targeted and endosome-targeted ovalbumin (Figue 4A and 4B). UBC9 overexpression only
moderately increased H- SIINEKL levels on cells transfected with cytosolic
ovalbumin (N50-0V A) (Figue 4c). This initially suggested that UBC9 might enhance
degradation ofER proteins specifically, for example by increasing retrograde translocation
of the protein into the cytosol. However, cytosolic ovalbumin is very unstable (see below),
which means that it is quickly degraded and may provide more peptides to MHC class I
molecules. Since transient transfection leads to very high levels of protein expression in
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Fig 4: Ubc9 over-expression increases Kb-SllEKL level on cells transfected with
many forms of ovalbumin. COS-Kb cells were co-transfected with pTracer-CMV-Vector
or pTracer-CMV-Ubc9, and with pcDNA3. CD16-0V A-LAMP. 1 (trgeted to the
lysosome), pcDNA3. CD16-0V A (ER-tageted), pcDNA3. N50-0V A (cytosolic), or
pcDNA3. Minigene (MSIIKL). Twenty-four hours after transfection, the cells were
stained with H-2Kb-SIIK- specific antibody 25.D1.1 and GFP+ cell populations were
analyzed by flow cytometr.
these COS cells, an alternate explanation was that expression of cytoplasmic ovalbumin
leads to satuation ofH- SIINFEKL levels. This may obscure any enhancing effect of
UBC9. As well , in transient transfections a potential complicating factor is interference
between the co-transfected ovalbumin-expressing and UBC9-expressing plasmids. Both of
these concerns could be at least partially addressed with stable transfectants, since stable
constrcts tend to express lower levels of protein and since I would be able to transiently
trans feet the cells with just a single plasmid, which would eliminate the potential
interference of co-transfection.
1.3. UBC9 effects on stable ovalbumin transfectants
I generated several stable transfectats expressing ER-tageted ovalbumin and cytosol-
targeted ovalbumin (Fig 5A). I then transiently transfected these stable transfectants with
pTracer-CMV vector, pTracer-CMV-UBC9 , or pTracer-CMV-UBC90H. Twenty-six hours
after transfection, the cells were analyzed by flow cytometr, and GFP-positive cell
populations were analyzed (Fig 5B). In contrast to the transiently transfected cells, in the
stable transfectants UBC9 overexpression markedly increased H- SIINEKL levels not
only on ER-targeted ovalbumin (CDI6-0va), but also on cytosolic ovalbumin (N50-0va)
transfected cells. Therefore UBC9 overexpression increases H- SIINEKL level from
ovalbumin regardless of its subcellular location.
1.4. UBC9 does not increase H- SIINEKL levels by enhancing the synthesis of
ovalbumin
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Fig 5. Ubc9 overexpression increases H-2Kb-SIINFEKL levels on COS-Kb ceUs stably
transfected with ovalbumin. A. Two clones of COS-Kb stably expressing C016-0V A (ER-
tageted), and two clones expressing N50-0V A (cytosolic) ovalbumin were stained with
anti- 2Kb-SIINKL antibody 25.01.16 and analyzed by flow cytometr. B. Stable
ovalbumin transfectants were transfected with pTracer-CMV -Vector, or pTracer-CMV-
Ubc9. Thrty-six hours after transfection, the cells were stained with 25.01.16 and GFP+
populations were analyzed by flow cytometr.
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The first steps in the MHC class I pathway are the transcription and translation of cellular
and viral proteins. Because UBC9 has been found to regulate some transcription factors
(148 , 164, 169 , 197- 199), it seemed possible that UBC9 could be increasing H-
SIINFEKL levels by increasing the synthesis of antigen from the transfected constrcts
even though the stable protein levels were similar (Figure ID). I therefore performed
protein loading experiments to bypass antigen synthesis. In these experiments, purfied
antigen is directly loaded into the cytosol of live cells, where it is processed by proteasomes
and the peptides generated are presented by MHC class I molecules. Cells transfected with
pTracer-CMV -UBC9 or control plasmid were loaded with ovalbumin by hypertonic lysis of
pinosomes (which delivers that antigen into the cytosol) and then grown in normal medium
at 37 C. Surace H- SIINEKL levels were analyzed by flow cytometr at different
time points (Fig 6). About 30 minutes after protein loading, H- SIINEKL complexes
appeared on the cell surace, and reached their maximum level about 2 hours after protein
loading. UBC9-transfected cells always expressed higher levels of H- SIINEKL than
control vector-transfected cells. Therefore either UBC9 enhanced presentation from
hypertonic ally-loaded protein, or UBC9 enhanced the uptake of proteins from extracellular
medium. To know whether UBC9 increases protein uptake in protein loading experiments
I quantified the amount of protein loaded into cells by using a fluorescent-tagged protein
(Cy5-conjugated goat anti-mouse IgG). F ACS results showed that UBC9 did not increase
protein uptae (Fig 7). Therefore UBC9 overexpression affects MHC class I antigen
presentation step(s) after protein synthesis, and UBC9 does not increase H- SIINEKL
levels by enhancing the transcription and synthesis of antigen.
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Fig 6. UBC9 overexpression increases antigen presentation in cell loaded with
ovalbum protein. COS-Kb cells were transfected with pTracer-CMV vector or pTracer-
CMV-Ubc9, Thi-six hours after transfection, the cells were loaded with ovalbumin
(80mg/ml) by hypertonic lysis of pi no somes, incubated at 37 C, and staned with 25.D1.16
antibody at different time points. GFP+ cell populations were analyzed by flow cytometr.
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Fig 7. Ubc9 over-expression does not increase protein uptae. COS-Kb cells were
transfected with pTracer-CMV-Vector or pTracer-CMV-Ubc9. Thiry-six hours after
transfection, the cells were loaded with Cy5-conjugated goat anti-mouse IgG antibody by
hypertonic lysis of pinosomes and incubated at 37 C. The cells were analyzed by flow
cytometr at 0 min, 30 mins and 120 mins.
1.5. UBC9 does not increase MHC class I antigen presentation by increasing degradation
of antigenic proteins
After antigens are synthesized, the next step in the MHC class I pathway is the
degradation of the antigen into oligopeptides. Although most studies have shown that UBC9
sumoylates target proteins and modifies the function of the targeted proteins, there are some
examples where UBC9 enhances the degradation of certain proteins (127 , 128). To
determine whether UBC9 up-regulates MHC class I antigen presentation by accelerating
antigenic protein degradation, I performed pulse-chase experiments. Cos- cells were co-
transfected with plasmids expressing cytosolic ovabumin (N50-0va) and either UBC9 or
vector alone. Twenty eight hours after transfection, the cells were pulse-labeled with S for
5 minutes and chased for 15 to 90 minutes. Lysates were immunoprecipitated with rabbit
anti-ovalbumin antibody (Fig 8). UBC9 did not change the rate of degradation of
ovalbumin. Therefore UBC9 does not increase MHC class I antigen presentation by
regulating the overall rate of protein degradation.
6. Ovalbumin protein degradation is proteasome dependent
Most MHC class I presented peptides (including SIINEKL from ovalbumin) are
generated by proteasomes (8). It was possible that UBC9 was stimulating some other
proteolytic pathway that was generating SIINFEKL. Therefore, I sought to verify that the
increase in antigen presentation in UBC9-transfected cells was stil proteasome-dependent.
Cos- cells were transfected with either control vector or UBC9 , and hypotonically loaded
with ovalbumin. After protein loading, the cells were grown in normal medium or in the
presence of proteasome inhibitor MG 132 for 8 hours (Fig 9). The proteasome inhibitor
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Fig B. USCg and USC9 OH do not strongly increase protein degradation.
COS-Kbce!\s were co.transfected with pTracer.CMV-N50-0VA and
pTracer-CMV vector, pTraver.CM\l.USC9 or pTracer-CMV-UBC90H.
Twenty-four hours a1tertransfection , the cells are labeled with 35S- Metfor
5 minutes and then chased for up to 90 minutes. Immunoprecipitation were
done wtth rabbit anti-OVA antibody.
, l
Normal Medium MG 132 Medium
100 100
1000
1d 60
.. 40
1d 60
.. 40
100
I'L2-
Kb-SIINEKL
Isotye IgGControl - 25.Dl.
Fig 9. MHC class I antigen presentation is proteasome-dependant in the
presence of UBC9. Cos-Kb cells were transfected with pTracer-Ubc9. Thir-
six hours after transfection, the cells were pre-incubated in MG 13- contaning
medium (50 M) for 1 hour. The cells were loaded with ovalbumin (80mg/ml) by
hypertonic lysis of pinosomes and incubated in the presence of MG 132 for 3
hours. The cells were then staned with 25.Dl. 16 antibody and GFP+ cells were
analyzed by flow cytometr.
almost completely inhibited MHC class I antigen presentation. This result demonstrates that
even in the presence ofUBC9 , MHC class I antigen presentation is stil proteasome
dependent.
3.2. Analysis ofUBC9 effects on oligopeptide constrcts.
To fuher investigate whether UBC9 might enhance the generation of presented
peptides by proteasomes, I used antigen constrcts that did, or did not, require proteasomal
cleavage for the generation ofH- SIINEKL complexes. I made use of mini genes
consisting of the epitope SIINFEKL with short N- or C-terminal extensions, which our lab
and others have shown to have specific requirements for antigen processing (47). For
example , because carboxypeptidase activity is not present in the cytosol of most cells, any
SIINEKL precursors with even a single C terminal extension are dependent on proteasome
activity for presentation of the matue epitope SIINEKL. In contrast, SIINEKL with
short N-terminal extensions can bypass the proteasome, with cytosolic and ER
aminopeptidases generating the matue SIINEKL epitope. SIINEKL can also be targeted
directly to the ER with a signal sequence, so that cytosolic proteases and the TAP
transporter are bypassed altogether. To rule out the possibilty that UBC9 may affect MHC
class I antigen presentation by affecting minigene transcription/translation, I also did
experiments loading synthetic peptides directly into the cytosol , including N-terminal
extended peptides (which require aminopeptidases for presentation), C-terminal extended
peptides (which require proteasomes), and SIINEKL peptide (which does not require any
trmming).
1. UBC9 overexpression regulates proteasome-dependent presentation.
My previous results showed that UBC9 overexression increased H- SIINEKL
levels transfected with all forms of protein. I asked whether UBC9 regulates proteasome-
dependent presentation. When COS- cells were transfected with C-terminal extended
SIINEKL minigene and UBC9 or control vector, UBC9 transfected cells expressed higher
level ofH- SIINEKL than control plasmid transfected cells (Fig lOA). Even when
UBC9 transfected cells were loaded with SIINEKLT (which has a single extra C-terminal
flankng residue), the H - 2K b -SIINEKL level was much higher than control plasmid
transfected cells (Fig lOB). Considering the requirement for proteasomes for presentation
of SIINEKL from C-extended peptide, this suggested that proteasome-dependent
presentation (or an event(s) downstream of the proteasome) is regulated by UBC9.
3.2.2. Ubc9 overexpression enhances N-terminal extended peptide presentation
Following the pathway ofMHC class I antigen presentation, after longer oligopeptides
are generated by proteasomes , the peptides are trmmed by aminopeptidases to generate the
correct-sized peptides. Does UBC9 overexpression affect presentation ofN-terminal-
extended peptides? UBC9 only moderately increased levels ofH- SIINEKL when
UBC9 was transiently co-transfected with N-extended SIINEKL minigene constrcts (Fig
11). However, as with the cytosolic ovalbumin (N50-0V A) described above, it seemed
possible that the high expression level of minigenes in transient transfections may satuate
cell surace H- SIINFEKL expression, disguising the effect ofUBC9.
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Fig 10. Ubc9 overexpression increases H- SIIEKL presentation from C-
terminal-extended precursors. A) COS-Kb cells were co-transfected with C-termnal-
extended SIINFKL (C- 15) and pTracer-CMV-Vector or pTracer-CMV-Ubc9. Twenty-
eight hours after transfection, the cells were stained with 25.D 1. 16 antibody, and GFP +ve
cells were analyzed by flow cytometr. (B) COS- cells were transfected with pTracer-
CMV-Vector or pTracer-CMV-Ubc9. Twenty-eight hours after transfection, the cells
were loaded with SIIKLT (lmg/m)l , incubated for 2 hr, stained with 25.DL16
antibody, and GFP +ve cells were analyzed by flow cytometr.
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Fig 11. Ubc9 overexpression increases H-2Kb-SllNFEKL presentation from N-
terminal-extended precursors. COS-Kb cells were co-transfected with pTracer-CMV-
Ubc9 and SIINEKL minigene with 5 (N5) or 15 (N15) extra amino acids at the N-
terminus. Thirt-six hours after transfection, the cells were staned with 25.D1.16 , and
GFP +ve cells were analyzed by flow cytometr.
I therefore made tetracycline-inducible ovalbumin and SIINEKL minigene expression
plasmids, so that expression levels of the protein or peptides could be controlled. When
Cos-Kb cells were co-transfected with pTet-ON-UBC9 and pBI-EGFP-CDI6-0V A or pBI-
EGFP-N50-0V Aand induced with doxycyclin, the H- SIINEKL levels on UBC9-
transfected cells were higher than on control vector transfected cells (Fig 12). This was
consistent with our previous observations with UBC9 expression vectors, and confirmed
that the inducible vectors could be used in these assays. I co-transfected pTet-ON-UBC9
with pBI-EGFP- terminal extended-minigene (N5-minigene, expressing
LEQLESIINEKL
). 
Twenty-six hours after transfection, the cells were acid-washed to
remove preexisting peptide-MHC complexes and grown in doxycyclin-containing medium
for induction and stained for SIINEKL-Kb complexes. Flow cytometr analysis showed
that UBC9 overexpression slightly increased N-terminal extended peptide presentation (Fig
13 a).
I also did similar experiments loading synthetic N-extended SIINEKL peptides into
the cytosol of cells. UBC9-transfected cells expressed higher level of H- SIINEKL
than control plasmid transfected cells when loaded with N-extended SIINEKL peptide (Fig
13b).
3. UBC9 overexpression increases SIINEKL peptide presentation
UBC9 enhanced both N-extended and C-extended SIINEKL presentation, so the next
question is whether UBC9 had an effect on presentation of SIINFEKL itself. UBC9 did not
increase H- SIINEKL levels in cells transfected with either constitutive or inducible
expression plasmids (Fig 14A and 14B). Interestingly, however, when synthetic SIINEKL
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Fig 12. Ubc9 increases H-2Kb-SIINFKL levels from cells inducible expressing
ovalbumin. COS-Kb cells were co-transfected with pTet-ON-Ubc9 and pBI-EGFP-CDI6-
OVA, or pTet-ON-Ubc9 and pBI-EGFP-N50-0V A. Twenty hours after transfection, the
cells were acid-washed and grown in DOX (20l-g/ml) containing medium. After a furher 4
hours incubation, the cells were stained with 25.D1.16 antibody, and GFP +ve cells were
analyzed by flow cytometr.
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Fig 13. Ubc9 overexpression increases H-2Kb-SIINEKL levels from N-
terminal extended SIINFEKL precursors. A: COS-Kb cells were co-transfected
with pTet-ON-Ubc9 and pBI-EGFP-N5-SIIKL. Twenty hours after transfection
the cells were acid-washed and grown in DOX (20Ilg/nll) containing nlediunl. 
varous tinle points the cells were stained with 25.Dl.16 antibody, and GFP +ve cells
were analyzed by flow cytonletr. B: COS- cells were transfected with pTracer-
CMV -Vector or pTracer-CMV - Ubc9. Twenty-eight hours afer transfection, the cells
were loaded with N-extended LEQLESIINKL (O.2nlg/rn). At varous tinle points
the cells were stained with 25.Dl.16 and GFP +ve cells were analyzed by flow
cytonletr .
peptide was hypertonically loaded directly into the cells (with subsequent acid washing to
remove peptide bound directly to surace-resident H- ), UBC9-transfected cells did
express higher levelsofH- SIINEKL than control plasmid-transfected cells (Fig 14C).
The inconsistency may reflect the difference between the minigene-encoded sequence and
the synthetic SIINFEKL peptide, in which the minigene expression product has an extra
non-native residue, Met, at the N-terminus as the initiation codon, so that some
aminopeptidase trmming is required. To know whether this additional N-terminal amino
acid has any effect on peptide processing, we made a MIINEKL minigene expression
plasmid; the translation product of this cDNA wil be an eight residue peptide that wil
require no fuher trmming. The affnity ofMIINEKL to H- molecules is similar to
SIINEKL, and recognition ofMIINEKL- by 25.D1.16 is smilar to that of
SIINEKL- (1). When the MIINEKL minigene was co-transfected with UBC9
more H- MIINFEKL complexes on cell surace were observed than in control vector-
transfected cells (Fig 14D), which was consistent with the SIINEKL peptide-loading
experiments results. Although we do not know why the initiating methionine on
MSIINEKL has such an effect on peptide processing and presentation, UBC9 clearly can
increase antigen presentation of SIINFEKL from all forms of ovalbumin antigens.
2.4. UBC9 affects ER processes
Peptides generated in the cytosol are transported into ER via an ER-membrane
complex TAPlITAP2. In the ER, peptides are bound to empty MHC class I molecules.
Many ER proteins are involved in this process, including ER chaperones such as calnexin
calreticulin, and ERp57 , and tapasin (98) (99), which tethers empty MHC class I molecules
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Fig 14. Ubc9 over-expression increases H- SIINKL levels on cells loaded
with SllNFEKL peptide or transfected with MlFEKL minigene. A. COS-
cells stably expressing MSIIKL were transfected with control vector or UBC9.
Twenty-four hours after transfection the cells were stained with 25.D1.16 antibody
and GFP +ve cells were analyzed by flow cytometr. B: COS- cells were co-
transfected with pTet-ON-Ubc9 and pBI-EGFP-SIINKL minigene. Twenty-four
hours after transfection, the cells were acid-washed and grown in DOX (20fAg/ml)
containing medium. C: Empty vector or UBC9-transfected cells were loaded with
SIIKL peptide (O. lmg/ml), acid washed and incubated for 2 hours, and then
stained with 25.Dl.16 antibody. D: COS- cells were co-transfected with
MIIKL minigene and pTracer-CMV-Vector or pTracer-CMV-Ubc9. Twenty-
four hours after transfection the cells were stained with 25.D1.16 antibody and GFP
+ve cells were analyzed by flow cytometr.
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and TAPl/TAP2 complex together (35 200). To know whether UBC9 affects MHC class I
antigen presentation by regulating components in ER lumen, I made an inducible ER-
tageted SIINFEKL minigene expression plasmid, in which the SIINEKL epitope is
translocated into the ER lumen by a signal sequence. When COS- cells were co-
transfected with UBC9 and the ER-targeted mini gene and induced with tetracyclin, UBC9
increased H- SIINEKL levels on the surace (Fig 15), suggesting that UBC9 may
affect MHC class I antigen presentation by regulating ER components.
5. ICP47 does not affect UBC9 fuction in regulating ER-tageted minigene
presentation
Presentation ofSIINFEKL from the ER-targeted minigene should be TAP-independent.
However, it was also possible that a significant amount of the presentation from this
constrct was from peptide that was mistranslated or mistargeted and that never reached the
ER (e. , defective ribosomal products (DRiPs) or mistargeted molecules). This form of
presentation would not require ER components to be altered, and would be TAP-dependent.
It is also possible that peptides are retrotranslocated from the ER into the cytosol and
processed there. To rule out the possibilty that UBC9 affects ER protein presentation by
affecting cytosolic factors, I used the herpes simplex virs protein ICP47 to study the
fuction ofUBC9 on ES-minigene presentation. ICP47 inhibits MHC class I antigen
presentation by blocking the TAPl/2 complex (110, Ill). Twenty-four hours before
transfection, COS- cells were infected with a replication-defective recombinant
adenovirus that expresses ICP47 (110, 111). As expected, ICP47 efficiently inhibited MHC
class I presentation from full-length ovalbumin (Figue 16A), and markedly decreased
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Fig 15. Ubc9 increases H-2Kb-SIINKL levels on cells transfected with ER-
targeted SllNFKL miigenes. COS-Kb cells were co-transfected with pBI-EGFP-ES-SIIKL (SIINKL targeted to the ER by a signal sequence) and pTracer-CMV
vector or pTracer-CMV-Ubc9. Twenty hours after transfection , the cells were acid-
washed and grown in DOX (20""g/ml) contaning medium. At varous times the cells were
stained with 25.D1.16 antibody and GFP +ve cells were analyzed by flow cytometr
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Fig 16. ICP47 does not inhibit Ubc9' s up-regulation of H-2Kb-SIINFEKL on
cells transfected with ES-miigene. Control adenovirs, or Ad-ICP47, -infected
COS-Kb cells were transfected with different pTracer-SRa-CDI6-0V A (A), pTracer-
SRa-minigene (B), or pBI-EGFP-ES-minigene with pTet-ON-Vector/pTet-ON-Ubc9
(C). Twenty-six hours after transfection, the cells were stained with 25.D1.16
antibody (A and B), or the cells were acid-washed and grown in DOX (20 g/ml)
containing medium for 4 hours , and then stained with 25.D1.16 antibody (C). GFP+
cell populations were analyzed by flow cytometr.
SIINEKL minigene presentation (Fig 16B), but did not affect presentation of SIINEKL
from the ER-targeted minigene (Figue 16C), which bypasses the TAP blockade. Even in
the presence ofICP47 , UBC9 increased H- SIINEKL level when COS- cells were
transfected with ER-tageted minigene (Fig 16C). These results suggested that UBC9
affects MHC class I antigen presentation by regulating ER components.
6. UBC9 overexpression increases H- SIINFEKL level on E36- cells
transfected with all forms of SIINEKL minigenes
In addition to the experiments using Cos- cells described above, I also used H-
transfected hamster cells, E36- , to study the fuction ofUBC9 in MHC class I antigen
presentation. In these experients, E36- cells were transfected with UBC9 and several
SIINEKL minigenes , including Nl5-minigene (encoding
LVLLPDEVSGLEQLESIINFEKL), N5-minigene (encoding LEQLESIINEKL), C5-
minigene (encoding SIINEKLTEWTS), Cl5-minigene (encoding
SIINEKLTEWTSSNVEERKK), ER-targeted SIINFEKL minigene, and MSIINEKL
minigene. Fort-eight hours after transfection, the cells were analyzed by flow cytometr
(Fig 17). UBC9 overexpression increased cell surace H- SIINFEKL levels on E36-
cells transfected with all forms of mini genes, suggesting a role ofUBC9 in regulating MHC
class I antigen presentation. Notably, in E36- cells, MSIINEKL minigene presentation
was augmented by UBC9, which is in contrast to the COS- transient tranfection
experiments described above. Not as shown in figue 14; in which SIINEKL minigene
was unaffected by UBC9 whether inducible or constitutive. It was consistent with the
peptide and the MIINEKL results.
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Fig 17. Ubc9 overexpression increases H-2Kb-SllEKL level on E36.Kb cells
transfected with several SllNFEKL precursors. E36-Kb cells were co-transfected
with combinations of plasmids as noted. Fort-eight hours after transfection, the cells
were staned with 25.D1.16 antibody, and GFP+ cell populations were analyzed by
flow cytometr. NI5-SIINKL and N5-SIINKL: N-extended SIINKL. C5-
STIKL and CI5-STIKL: C-extended SIINKL. ES-SIIKL: STIKL
targeted to the ER by a signal sequence. STIKL: MSTIKL minigene.
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3.3. UBC9 does not regulate MHC class I antigen presentation by regulating
aminopeptidases or protecting peptide from degradation.
3.3 . 1. UBC9 does not regulate aminopeptidases
Proteasomes generate peptides whose length is 4-24 amino acid residues (43). The C-
terminus of peptides presented by MHC class I molecules must be generated by
proteasomes, but N-terminal amino acids can be trmmed from longer peptides to generate
the correct N-terminus (29 , 46 , 47). These longer peptides are trmmed by aminopeptidases
which exist both in the cytosol and the ER lumen. So far, at least four aminopeptidases have
been found to playa role in trmming precursors of antigenic peptides: leucine
aminopeptidase (48), bleomycin hydrolase (BH), puromycin sensitive aminopeptidase
(PSA) (49, 201), and ER aminopeptidase 1 (ERA1) (1, 91), also termed ER
aminopeptidase associated with antigen processing (ERA) (90).
My peptide-loading experiments showed that UBC9 increased H- SIINEKL levels
on cells loaded with all forms of SIINEKL and its precursors. While the most dramatic
effect was seen on C-terminal extended peptides, which require the proteasome for
SIINEKL generation, significant increases were also seen on N-extended peptides , which
do not depend on the proteasome for SIINEKL generation. The results suggested that even
ifUBC9 regulates MHC class I antigen presentation by regulating the activities of
aminopeptidases , aminopeptidases are not the only affected step.
It has been reported that one aminopeptidase, BH, binds to Ubc9 (202), suggesting that
Ubc9 may regulate H- SIINEKL by regulating aminopeptidase activity. Consistent
with this possibility, I found that UBC9increased levels ofBH protein when the genes were
co-transfected (Fig 18). To more specifically examine the effect ofUBC9 on specific
aminopeptidases, COS- cells were co-transfected with ovalbumin and either BH or PSA.
Both BH and PSA increased H- SIINEKL levels when co-transfected with full length
ova (Fig 19) , though PSA' s effect was very slight. We co-transfected COS- cells with
, an inactive mutant ofBH, UBC9, or a control gene, ORP150. Twenty-eight hours after
transfection, the cells were loaded with ovalbumin protein, and analyzed by flow cytometr.
Co-transfections with UBC9 and wild tye or mutant BH had no more effect on H-
SIINEKL levels than did transfection with UBC9 alone (Fig 20), presumably because BH
levels were now not limiting and/or peptide amounts generated are satuating. Therefore
part of the effect ofUBC9 on antigen presentation ofN-extended precursors may be through
its increasing BH. However, this canot account for the effect ofUBC9 on the C-terminal-
extended SIINEKL precursors, or (since BH is a cytosolic enze) on the ER-targeted
SIINEKL.
2. UBC9 does not regulate MHC class I antigen presentation by protecting peptide
from degradation
The finding that UBC9 increased H- SIINFEKL level on cells loaded with all forms
of SIINFEKL peptides suggest another mechanism by which UBC9 could increase antigen
presentation: by decreasing the destrction of pep tides. For example, an endopeptidase
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Fig 18. Ubc9 increases the levels of co-transfected bleomycin hydrolase. Cos-
cells were transfected with pcDNA3. 1/HisB-Xpress-HuBH and Ubc9 or Vector.
Twenty-four hours after transfection, the cells are lysed and whole celllysates are
subjected to western blot with anti- press antibody. Lane 1: HuBH+pTracer vector;
lane 2: HuBH+pTracer-UBC9. Lane 3 and lane 4 are load with 1/3 of the amount of
lysates of lane1 and lane 2 respectively.
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Fig 19. Overexpression of peptidases afects MHC class I antigen
presentation. COS-Kb cells were co-transfected with plasmids expressing no
insert (left column), bleomycin hydrolase (second column), puromycin-
sensitive amnopeptidase (thd column), or thmet oligopeptidase (rightmost
column) and the indicated ovalbumin plasmids. Fort-four hours after
transfection, the cells were staned with 25.D1.16 and GFP +ve cells were
analyzed by flow cytometr.
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Fig 20. Ubc9 does not further increase H-2Kb-SIINFEKL levels in
cells transfected with bleomycin hydrolase. COS-Kb cells were
transfected with lasmids expressing Ubc9, Ubc9 and BH, or Ubc9 and
an inactive mutant ofBH. Twenty-eight hours after transfection, the
cells were loaded with ovalbumin, incubated at 37 , and stained with
25.D 1. 16 antibody at different time points. GFP +ve cells were
analyzed by flow cytometr.
thimet oligopeptidase (TOP), has been found to destroy peptides and thereby reduce MHC
class I antigen presentation (Fig 19) (195). Inhibition of TOP (69), or other destrctive
peptidases (1) increases MHC class I presentation by reducing peptide destrction.
Therefore, we asked if UBC9 might protect peptides from degradation. In this experiment, I
used COS7 cells , rather than COS- , in order to avoid the complication ofSIINEKL
binding to H- and being protected from peptidases. COS7 cells were transfected with
control vector or UBC9 plasmid. Thir-six hours after transfection, cytoplasmic extracts
were prepared and ESIINEKL peptide was incubated with the extracts and analyzed by
RP-HPLC at intervals. Peptide was degraded at very similar rates from extracts of control
and UBC9-transfected extracts, showing that UBC9 did not protect peptides from
degradation (Fig 21).
We also examined peptide stability in intact cells. pTracer-CMV -vector or pTracer-
CMV-UBC9 plasmid-transfected COS7 cells were hypertonically loaded with SIINEKL
peptide and grown at 37 oC. At different time points peptides were extracted with 10%
TCA or TF A, and used for antigen presentation assays (Fig 22). Again, UBC9 did not
protect peptides from degradation.
3.4. UBC9 overexpression increases the levels of several proteins in the antigen
presentation pathway
3.4. 1. UBC9 upregulates immunoproteasome components
'C 40
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Fig 21. Ubc9 overexpression does not protect peptides from degradation.
COS-7 cells were transfected with pTracer-CMV -Vector or pTracer-CMV-
Ubc9. Thir-six hours after transfection, the cytosol was extracted as
described in the Materials and Methods and used for ESIINKL peptide
digestion. Peptide degradation rates were analyzed by HPLC on a C 
column.
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Fig 22. Ubc9 overexpression does not protect peptides from degradation. COS-7 cells
were transfected with pTracer-CMV -Vector or pTracer-CMV -Ubc9. Twenty-eight hours after
transfection , the cells were loaded with SIIFEKL peptide, acid-washed, and incubated at
C. At various times the cells were lysed with 5% TFA, and peptides were extracted and
used to stimulate the H-2Kb-SIIKL-specific hybridoma RF33.70 as described in the
Methods and Materials. Shown is the IL-2 release from RF33.70 as measured by
incorporation of 3H-thymidine by the IL2-dependent cell line CTLL.
UBC9 increased H- SIINEKL levels more from C-terminal-extended minigenes
than from N-terminal extended constrcts or from SIINEKL itself. Since C-terminally-
extended peptides require proteasomes for processing and presentation on MHC class I
molecules (46 , 47), this finding suggested that UBC9 might be affecting proteasomes.
Although we found that UBC9 did not change the protein degradation rate (Figure 8), it was
possible that UBC9 may modify the components of the proteasome, or regulate the activity
of proteasome components in ways that alter the cleavage pattern of antigens, so that
proteasomes more effciently generate antigenic peptides from degraded proteins. It has
been shown that immunoproteasomes, in which the catalytic 131 , 132, and 135 subunits have
been replaced by LMP2 , LMP7 , and MECL- , generate different peptides than do
constitutive proteasomes , releasing from ovalbumin 2-4 times more of certain N-extended
versions of SIINFEKL (29) that can be processed to the matue epitope, so that more
antigenic peptides are ultimately generated per molecule of protein degraded. To know
whether UBC9 induced LMP2 , LMP7 and MECL- , COS- cells overexpressing UBC9
were stained with mouse anti-UBC9 and with anti-LMP2 , anti-LMP7 or anti-MECL-
antibodies and examined by fluorescent microscopy (Fig 23A, 23B and 23C). The cells
were transfected under conditions so that only a minority of cells expressed UBC9, so that
neighboring untransfected cells (not staining with anti-UBC9) could be used as controls. In
UBC9-transfected cells , the LMP2 , LMP7 and MECL- l staining was markedly stronger
than in adjacent untransfected cells. This was not because of spectral overlap between FITC
and rhodamine, because appropriate filters were used and several other proteins (e.
calnexin and calreticulin), stained as controls, showed no change in intensity in UBC9
expressing cells (see below). These observations suggested that UBC9 may increase the
amount of some immunoproteasome components.
3.4.2. UBC9 increases TAPI and Tapasin protein levels
Our transfection and peptide loading experiments showed that UBC9 overexpression
increased cell surace H- SIINEKL levels on COS- cells loaded with SIINEKL
peptide (Figue 14C), suggest that it may also regulate factors downstream of proteolytic
processing, such as TAP or other ER factors. Immunofluorescence experiments showed that
UBC9 upregulated TAPI and tapasin (Fig 23D and 23E), but had no effect on calnexin (Fig
23F), calreticulin (Fig 23G), ERp57 (Fig 23H), or PDI (Fig 231), or on the cytosolic protein
leucine aminopeptidase (LAP) (Fig 231).
3.4.3. UBC9 inhibits degradation of some proteins in the MHC class I presentation
pathway
The results above established that UBC9 increased the level of several proteins (LMP2
LMP7 , MECL- , TAPI and tapasin) that are associated with antigen presentation. The
increase in these proteins could be due to changes in their transcription or translation, or
may be due to post-translational effects. To know whether UBC9 increased these
components at the level of transcription, Real-Time PCR was used to analyze the levels of
MECL 1 mRA. Although MECL- l protein was markedly upregulated by UBC9
overexpression (Fig 23A), there was no difference in UBC9 mRA levels between vector
and UBC9-transfected cells (Fig 24), suggesting that UBC9 does not affect transcription of
this gene, and by extension the other genes whose protein levels increased.
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Fig 23. Ubc9 over-expression increases MECL- , LMP2, LMP7, TAPl, and
tapasin levels. Cos-Kb cells were transfected wIth a plasmid expressmg Ubc9. ThIrty
hours after transfectlOn, the cells were stamed with anti-UBC9 conjugated to FITC
and various other antibodies as mdIcated conjugated to Texas Red. The cells were
examined by confocal microscopy as descnbed in the Matenals and Methods.
Compare UBC9 transfected cells (red arrow) and un-transfected cells (yellow arrow),
UBC9 overexpression specifically increase MECLl , LMP2 , LMP7 , TAPI and
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Fig 24. MECL-lInRNA levels are not afected by UBC9 overexpression. mRA
was extracted from COS- cells transfected with Ubc9 or control vector and used
in RT-real-time PCR. A: internal control HPRT. mRA; B: MECL- l mRA.
Note: the traces are overlaed.
I then examined the effects of UBC9 overexpression on protein expression by western
blotting. Endogenous TAPI and TAPas in levels in COS cells were too low to be detected
with the antibodies used, or possibly the Afrcan Green Monkey protein in COS cells fails to
react with the anti-human antibodies that are available, and in the absence of IFN induction
MECL- , LMP2 , and LMP7 are expressed at very low levels that were also not detectable.
I therefore co-transfected plasmids expressing UBC9 and MECL- , LMP- , PA28a, or
PA2813. In the presence ofUBC9 , there was significantly more protein detected ofMECL-
, LMP- , P A28a, and P A2813 (Fig 25A-D).
Similarly, I co-transfected COS- cells with tapasin. We found that UBC9 itself did
not increase tapasin expression, but in the presence of co-transfected SUMO- , UBC9-
transfected cells expressed much higher levels of tapasin than did control vector-transfected
cells (Fig 26). Very interestingly, the catalytically inactive mutant UBC90H strongly
increased tapasin levels when co-transfected with tapasin (Fig 27). It is not clear why
UBC90H by itself affected tapasin while the wild tye UBC9 was only effective with
SUM02. Neverteless, both of these findings suggest that UBC9 regulates tapasin protein
levels, consistent with the immunostaining observations (Fig 23e)
UBC9 could increase protein levels without altering transcription either by increasing
translation, or by reducing protein degradation. To examine these possibilities, COS cells
were co-transfected with UBC9 , and LMP2 or PA2813. Twenty-four hours after
transfection, the cells were pulsed with S-methionine for 20 minutes, and then chased for
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COS-Kb cell were co- trafected with MECLl (A) IllIP2 (B) PA28a (C) PA28 (D) an
control vector, Ubc9 or Ubc90H. Twerd-four hour afer trafection, the cell were lysed 
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Fig 27. Ubc;90H overe ressioninreass taasleve. COS-Kb cell 'nere
co- trafected with tapasin an control vector, Ubc9 or Ubc90H. T1lnt-four
hoUl'S afer trafection. the cell 1lre lysed fUrl a 1lstern blot wa perfomLed
usin anti-tapasin fU\tibody.
up to 3 hours (PA2813) or 7 hours (LMP). In the presence ofUBC9 , MECL- l had
significantly longer half-lives , showing that UBC9 inhibited their degradation (Fig 28). 
contrast, UBC9 has no effect on the degradation rate of ovalbumin (see above and data not
shown). Therefore UBC9 selectively post-translationally regulates the expression of several
components of the MHC class I antigen presentation pathway.
5. siRNA-mediated elimination ofUBC9 does not decrease MHC class I antigen
presentation
Small interfering RNA (siRNA) has been used by many groups to eliminate or reduce
specific gene expression (1 203-206). To study the importance ofUBC9 in vivo, we used
siRNA to reduce UBC9 expression in COS-Kb cells. Twenty four hours after siRNA
transfection, UBC9 levels were much lower than untransfected and control-transfected cells
(Fig 29A), and three days after transfection UBC9 was almost completely undetectable (Fig
29B). When UBC9 siRNA-transfected cells were grown for more than 4 days , the cells
were very sick, with most cells becoming round, and losing adherence to the plate (data not
shown). When passed to another dish, the treated cell number did not increase (data not
shown), suggesting that in mammalian cells, as in yeast (123), UBC9 is essential for cell
viability.
The cytopathic effects ofUBC9 siRNA treatment make it difficult to interpret any
biological effects of UBC9 loss. With this caveat in mind, we studied the effects of
eliminating UBC9 on MHC class I antigen presentation. COS- cells were transfected with
MECL-l
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Fig 28. UB C9 o\rel':ql'ssion staiJs MECL-l. COS- ce ll were co-
trafected withplami expressin MECL-l an empty vector or UBC9. Twentoj-
four hour afer trafection, the cell were puled for 20 miutes an chased for
vaus tims, an inuunprecipitated usin anti-MECL-l antibody.
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Fig 29. siRA redw:es Ubt9lels in COS-Kb tell. CDS-Kb cell were tranfected with
siRA. One day (A) an thre days (B) afer trafection, the cell were lysed an western
blots were perionned using anti-UBC9 antibody.
UBC9 siRNA or control mTOP siRNA (1), and 3 days later, the cells were infected with
recombinant vaccinia virus expressing full-length ovalbumin, ER-targeted SIINEKL, or
MSIINFEKL for 7 - 8 hours , and analyzed by flow cytometr (Fig 30). Although we
expected that eliminating UBC9 would have the opposite effect to overexpression
surprisingly, UBC9 knockout increased the overall H- expression on the cell surface.
UBC9 knockout also increased H- SIINEKL levels on cells infected with vaccinia
virus expressing ER-tageted SIINFEKL and MSIINEKL, but not on cells expressing full-
length ovalbumin. This is in contrast to the results of UBC9 overexpression, in which
UBC9 dramatically increased H- SIINEKL level in full-lengt ovalbumin transfected
cells (Figue 4; Figue 5B). Nevertheless , in general, the findings that UBC9 inhibition
increased H- SIINEKL level on ER-target SIINEKL and MSIINEKL-expressing
cells contradict our prediction. Although we do not know the exact reason for this, one
possibility is that UBC9 elimination stresses the cells, which may in tu up-regulate
chaperones in the ER and enhance MHC class I assembly. Another possibilty is that these
results reflect an effect ofUBC9 on the proteasome, as we concluded with overexpression
studies. It is possible that, in the absence ofUBC9 , there wil be less proteasome-generated
peptides to compete with ES-SIINFEKL mini gene and SIINEKL minigene-generated
authentic peptides, which in tu have more chance to bind to empty MHC class I
molecules. However, we feel it is diffcult to draw any firm conclusions given the cytopathic
effects of eliminating UBC9.
6. Interferon treatment decreases UBC9 expression
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Fig 30. Ubc9 knockdown increases H-2Kb-SllNFEKL level from some
SIINEKL precursors. COS-Kb cells were transfected with control (mTOP) siRA
or Ubc9 siRNA. Four days after transfection, the cells were stained with Y3 antibody
(A), or infected with recombinant vaccinia virs (moi=lO) (B). Seven hours after
infection, the cells were staned with 25.Dl. 16 antibody and analyzed by flow
cytometr .
Both tye I and tye II interferon (IFN) have been shown to increase MHC class I antigen
presentation (207). A gene chip study showed that treatment of cells with the tye I IN-
inducer poly I::C up-regulated UBC9 mRA in dendrtic cells (208). It seemed possible
that one way in which IFN regulates MHC class I presentation is via UBC9. To test this, I
treated COS- cells with poly I::C, which induces tye I IFN generation, or with human
IFNy (HuIFNy). Both poly I::C and HuIFNy increased MHC class I expression level (Fig
31A), conftrming that the polyI::C and IFN were effective. However, these treatments
decreased UBC9 exp ess (Fig 3IB), suggesting that IFN does not increase MHC class I
antigen presentation by increasing UBC9 expression.
To know whether IFN,up-regulates UBC9 only in dendrtic cells, I used mouse bone
marow-derived primary dendrtic cells, and human monocyte-derived dendrtic cells.
These cells were treated with PolyI::C and IFNy. Both treatments decreased UBC91evel on
both kinds of dendrtic cells (Fig 32),conflling that (in contrast to the gene chip findings)
IFN does not up-regulate UBC9 expression.
7. SUMO-2 may be involved in UBC9 regulation ofMHC class I antigen
presentation.
UBC9 conjugates SUMO molecules, but not ubiquitin, to target proteins. In
mammalian cells, there are at least 3 forms of SUMO molecules, SUMO- I and two highly
homologous SUMO molecules - SUMO-2 and SUMO-3. Although (at least in COS cells)
there are more SUMO-2 and SUMO-3 molecules than SUMO- l (172), the fuctions of
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SUMO-2 and SUMO-3 in vivo are not known and no proteins modified by SUMO-2 or
SUMO-3 molecules in vivo have been identified. Since UBC9 conjugates SUMO
molecules to target proteins, we wanted to know which SUMO molecule(s) might be
involved in UBC9's regulation of MHC class I antigen presentation. SUMO molecules are
conjugated to their substrate lysine residue via their C-tenninal gly-gly motif (209). To
study this , I generated mutant SUMO-
, -
2 and - , in which their C-tenninal Gly-Gly
conjugating sequences have been mutated to ala-ala amino acids.. If a SUMO molecule is
involved in UBC9 fuction on MHC class I antigen presentation, transfection of a wild tye
SUMO should have different effects on MHC class I antigen presentation then its mutant
version; this should help distinguish specific from non-specific effects of the transfection.
The stably-transfected cell line 618-CDI6-0V A (COS-Kb cells stably expressing full-
length ovalbumin) was co-transfected with UBC9 together with either wild-tye or mutant
SUMO-
, -
, or -3. Twenty-six hours after transfection, the cells were analyzed by flow
cytometr (Fig 33). H- SIINEKL expression levels showed no difference between
cells transfected with wild-tye and mutant SUMO- lor SUMO-3 and UBC9. However
wild-tye SUMO- transfected cells expressed higher levels ofH- SIINEKL than did
mutant SUMO- transfected cells when co-transfected with UBC9, suggesting the
involvement ofSUMO-2 in UBC9 enhancement ofMHC class I antigen presentation. 618-
CD 16-0V A cells were then transfected with combinations of plasmids expressing UBC9
(wild-tye and mutant) and SUMO-2 (wild-tye and mutant). Thir hours after
transfection, the cells were analyzed by flow cytometr (Fig 34). SUMO-2 by itself, but not
mutant SUMO-2 by itself, increased H- SIINEKL level , and UBC90H by itself had
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Fig 33. Sumo2 and mutat Sumo-2 behave differently in Ubc9 reguating
MHC class I antigen presentation. COS-Kb cells stably expressing CDI6-0V A
were transfected with different plasmid combinations as indicated. Twenty-four
hours after transfection, the cells were stained with 25.Dl. 16 antibody and GFP+
cell populations were analyzed by flow cytometr.
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Fig 34. Sumo- , but not mutant Sumo- , over-expression increases Kb-SIINFEKL
level. COS-Kb cells stably expressing CD 16-0V A were transfected with plasmid
combinations as indicated. Thi hours after transfection, the cells were stained with
25.Dl. 16 antibody and GFP+ cell populations were analyzed by flow cytometr.
the same effect as UBC9 in regulating MHC class I antigen presentation, which is consistent
with our early finding. However, although co-transfection ofUBC90H and SUMO-
increased H- SIINEKL level on the cell surace, the co-transfection ofUBC90H with
mutant SUMO-2 eliminated the effect ofUBC90H itself, which was in contrast with the
results of co-transfection with UBC9 and mutant SUMO-2. In summary, mutant SUMO-
did not increase class I expression by itself and blocked the increase induced by mutant
UBC-9 (see table 3).
Table 3: Sumar of the effects of wild-tye and mutant UBC9 and
SUMO molecules on antigen presentation.
UBC9 SUMO Effect on Antigen Presentation
UBC9
UBC90H
SUMOI
SUMO I mut 
SUM03 
SUM03mut 
SUM02
SUM02mut 
UBC9 SUMO-
UBC9 SUMOImut
UBC9 SUM03
UBC9 SUM03mut
UBC9 SUM02
UBC9 SUM02mut
UBC90H SUM02
UBC90H SUM02mut
I also performed antigen loading experiments to confirm that SUMO-2 plays a role in
MHC class I antigen presentation. COS- cells were co-transfected with different UBC9
UBC90H, SUMO-2 and mutant SUMO-2 plasmid combinations. Twenty-eight hours after
transfection, the cells were loaded with ovalbumin protein and incubatedfor 2- 5 hours.
The cells were analyzed by flow cytomety (Fig 35). The results were very similar to the
transient transfection experiments shown above. When mutant UBC9 and mutat SUMO-
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Fig 35. Sumo-2 enhances MHC class I antigen presentation. COS-Kb cells were
transfected with different plasmid combinations as indicated. Twenty-eight hours afer
transfection, the cells were loaded with ovalbumin and incubated for 2 hours, stained with
25.D1.16 antibody, and GFP+ cell populations were analyzed by flow cytometr.
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were used in combination, the enhancing effect of UBC9 was almost totally lost, suggesting
the interaction ofUBC9 and SUMO-2 in MHC class I antigen presentation.
CHAPTER 
HSP27 AFFECTS MHC CLASS I ANTIGEN PRESENTATION
1 HSP27 overexpression reduces H- SIINEKL levels
To study how UBC9 regulates MHC class I antigen presentation, COS- cells were
cotransfected with UBC9 and 6xHis/Xpress tagged SUMO-2 or mutat SUMO-2. Twenty-
eight hours after transfection, the cells were lyzed and the lysates were subjected to
immunoprecipitation with NTA- 2+ bead. Western blot results showed a 38 kDa protein
was recognized by anti-Xpress antibody in SUMO- transfected, but not mutant SUMO-
transfected, celllysates. Therefore, this 38kDa band represented a SUMO-2 conjugated
protein (Fig 36A). HSP27 has been reported to interact with UBC9 in vivo (210). When the
membrane was probed with rabbit-anti-mouse HSP27 antibody, a band of 38 kDa was
detected (Fig 36B). However, fuher examination determed that the 38 kDa band was
actually a UBC9-SUMO-2 complex that coincidentally co-migrated with HSP27 (data not
shown).
Even though the original observation focusing my attention on HSP27 tued out to be
an artifact, I had perfonned experiments with HSP27 before this was resolved and found
that altering HSP27 expression did in fact affect antigen presentation. Hypothesizing that
UBC9 affects MHC class I antigen presentation by regulating HSP27, I cloned HSP27 by
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the cell were lysed an the lysates were applid to a NT A-Ni colum. After elution with
+ . western blots were pferfonnd on the eluates usmg anti-HSP:!1 antfuody. The
mow inates a han recogned hy anti-HSP27 anUbody.
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RT-PCR and co-transfected E36- cells with HSP27 and various SIINEKL precursors.
Nineteen hours after transfection, the cells were analyzed by flow cytometr (Fig 37).
HSP27 overexpression inhibited MHC class I antigen presentation of SIINEKL derived
from ovalbumin targeted to the ER, the cytosol, or lysosomes, from SIINFEKL targeted to
the ER, and from MSIINEKL itself. Although only small effects were seen in COS-
cells co-transfected with HSP27 and ER-tageted ovalbumin (Fig 38A), in protein loading
experiments with full-length ovalbumin COS- cells expressing HSP27 had significantly
lower levels ofH- SIINFEKL than control-transfected cells (Fig 38B). Thus HSP27
overexpression reduces MHC class I antigen presentation.
As with UBC9, HSP27 could affect any, or many, of the components ofthe antigen
presentation pathway. To know whether HSP27 inibits overall protein synthesis or protein
traffcking, E36- cells were co-transfected with pTracer-HA-HSP27 (encoding HA-
tagged HSP27) and pTracer-CD 16-0V A (encoding full-length ovalbumin), pTracer-CMV-
HI (encoding influenza virus HA), orpTracer-CMV-A*0302 (encoding HLA-A3) and
analyzed by flow cytometr (Fig 40). HSP27 did not affect protein synthesis (Figue 39)
but inhibited H- SIINFEKL expression, and also inhibited HA expression on the cell
surface (one of two times), but did not affect HLA-A3 expression. This result suggests that
HSP27 affects the transport of some, but not all, proteins to the cell surace. So , this effect
is not specific for MHC class I but instead affects several cell-surace glycoproteins.
2. Mutation of potential SUMO conjugation and phosphorylation sites does not affect
HSP27's effect on MHC class I antigen presentation
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Fig 37. Hsp27 overexpression down-regulates H-2Kb-SIINFEKL levels.
E36-Kb cells were co-transfected with different plasmid combinations as
indicated. Eighteen hours after transfection, the cells were stained with
25.Dl. 16 antibody and GFP+ cell populations were analyzed by flow
cytometry .
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Fig 38. Hsp27 overexpression decreases H- SDNFEKL generation from
ovalbumi protein. A, COS- cells were co-transfected with plasmids expressing
ovalbumin and control vector or pTracer-CMV-Hsp27. Twenty-four hours after
transfection, the cells were stained with 25.D1.16 antibody and GFP +ve cells were
analyzed by flow cytometr. B. COS- cells were transfected with control vector or
pTracer-CMV-Hsp27. Twenty-four hours afer transfection, the cells were loaded
with ovalbumin by osmotic lysis of pinosomes. After 1 hour incubation at 37 oC, the
cells were stained with 25.D1.16 antibody and GFP +ve cells were analyzed by flow
cytometr .
____-
105
pTraer-OV A pTraer-HLA-
t,.
Fig 39. 1U27 does not wre.e protein synthsi. COS-K"b cell were co-
tl'fected with p Traer-OV A and control vector or Hsp27 (A), or co-tl'fected with
pTraer-HLA-A3 an control vector or Hsp27. Twel'- four hour afer tl'fectiorl,
the cell 'Nere lysed an western blot s were perfonnd. Mernm:s were probed with
anti-OV A (A) or anti-A3 (HCA2) anibody respectivly
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Fig 40. 1U27 6ft. SIIEKl,H.2Kb and hemaguti but not HL- AJ,
e:\re.sin on ih ren sue. E36-Kb cell were co- tl'fe cted with Hsp27 
pTrael' CD16-0V A (A), pTraer-Hl (B) or pTraer-HLA- A0302b (C). Eiteen
hour afer tl'fection. the cell were staid with 25.01.16 (A), H36.4.2 (B), or GAP-
A3 (C), an GFP +l cell were anlyzed by flw cytomehy,
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We initially hypothesized that the effect ofUBC9 was related to its association with HSP27.
Since UBC9 conjugates SUMO molecules to lysines on taget protein, I mutated alllysines
in HSP27 individually to arginines. E36- cells were co-transfected with these mutant
HSP27 and pTracer-CD 16-0V A. I found that overexpression of all mutants of HSP27
inhibited MHC class I antigen presentation (Fig 41), suggesting HSP27 does not regulate
MHC class I antigen presentation via its interaction with UBC9. Consistent with this , when
COS-Kb cells were co-transfected with UBC9 and HSP27 , HSP27 was not found to be
modified by any SUMO molecule (data not shown).
HSP27 is a phosphoprotein. I mutated the three phosphorylation sites individually from
series to alanines. E36- cells were co-transfected with these mutant genes and pTracer-
CDI6-0V A, and analyzed by flow cytometr. No mutation was found to relieve the
inhibitory effect of HSP27 on MHC class I antigen presentation (Fig 42), implying that
phosphorylation is not involved in HSP27 fuction in MHC class I antigen presentation.
However, again, since I did not make double or trple mutations, I can not rule out the
possibility that kiases can use multiple phosphorylation sites to modify the protein, which
in tu affects MHC class I antigen presentation.
4.3. HSP27 knockout decreases MHC class I antigen presentation
To know how importnt a role HSP27 plays in MHC class I antigen presentation in
vivo, siRNA was used to reduce HSP27 expression. Four days after siRNA transfection of
COS- cells , HSP27 expression was almost completely eliminated (Fig 43). As with
UBC9 knockout cells , the cells lacking HSP27 were very sick and stopped growing, which
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Fig 41. Mutation of potential Sumo conjugation sites does not afect Hsp27'
inhibition of MHC class I antigen presentation. E36-Kb cells were co-
transfected with pTracer-CMV -CD 16-0V A and varous Hsp27 mutats as
described in the Materials and Methods. 18.5 hours after transfection , the cells
were staned with 25.Dl. 16 antibody and GFP +ve cells were analyzed by flow
cytometr .
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Fig42. Mutation of potential phosphorylation sites does not afect Hsp27'
s inhibition
of MHC class I antigen presentation. E36- cells were co-transfected with
pTracer-CMV-CD16-0V A and varous Hsp27 mutants as described in the Materials
and Methods. Foureen hours after transfection, the cells were stained with 25.D1.16
antibody and GFP+ cell populations were analyzed by flow cytometr.
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Fig 43. siRNA reduces levels of Ubc9 and Hsp27. COS- cells were transfected with
Ubc9-siRNA or Hsp27-siRNA. Four days after transfection , the cells were lysed and a
western blots was performed using anti-UBC9 and anti-HSP27 antibodies.
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is consistent with published data (211), suggesting that HSP27 may be essential for cell
viability. When HSP27-knockout COS- cells were transfected with several SIINEKL
precursors , H- SIINEKL levels on HSP27 knockout cells were always lower than on
untransfected cells or control siRNA-transfected cells (Fig 44A): indeed the overall MHC
class I level on HSP27 knockout cells was lower than on un-transfected cells and control
siRNA transfected cells (Fig 44B). Similarly, when COS-7 cells were co-transfected with
HSP27 and H- or H- , 10werMHC class I expression level on HSP27-transfected
cells was observed than in control transfected cells (Fig 45). Interestingly, elimination 
HSP27 had no effect on HLA-A3 expression, which is consistent with HSP27
overexpression experients. The lack of an effect on HLA-A3 may reflect a difference in
peptide supply that is dependent on the paricular peptide motif bound by this class I allele
(which is somewhat unusual in its preference for binding peptides with basic C-termini).
However, in light of the effect of HSP27 on influenza hemagglutinin, it seems more likely
that the effect of HSP27 is on glycoprotein transport or degradation in general, and for an
as-yet unown reason HLA-A3 is less affected by this than are H- and H-
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Fig 44. Hsp27 knockdown decreases H-2Kb-SllKL levels on cells transfected with
various ovalbumin genes. COS-Kb cells were transfected with control (mTOP) siRA or
Hsp27-siRA. Thee days after transfection, the cells were transfected with pTracer-Sra-
CDI6-0V A (expressing full-length ovalbumin tageted to the ER), pTracer-Sra-ES-minigene
(expressing SIINKL targeted to the ER by a signal sequence), or pTracer-Sra-minigene
(expressing MSnNFKL in the cytosol). Twenty-two hours after transfection, the cells are
stained with Y3 antibody (A), or 25.D1.16 antibody (B) and GFP+ cell populations were
analyzed by flow cytometr.
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Fig 45. Hsp27 overexpression decreases levels of some cell-surface glycoproteins.
COS-7 cells were co-transfected with plasmids expressing Hsp27 and H- , HLA-
A*0302 , H- , or influenza hemagglutinin (HI). Fort-eight hours afer transfection,
the cells were stained with appropriate antibodies and GFP+ cell populations were
analyzed by flow cytometr.
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CHATER V: DISCUSSION
1. UBC9 overexpression increases antigen presentation
In our studies of the effects of ubi quit in-conjugating enzes on protein degradation
and MHC class I antigen presentation
, we originally used UBC9 as a control
, since UBC9
conjugates SUMO , rather than ubiquiti, to target proteins (131 , 132), and SUMO
conjugation does not generally lead to protein degradation (149
, 150). Unexpectedly, UBC9
overexpression significantly enhanced antigen presentation. Co-transfection of ovalbumin
and UBC9 increased cell surace H- SIINEKL levels about 6- to 10-fold, compared to
cells co-transfected with control vector and ovalbum (Fig 1). The effect was not due to an
increase in H- protein synthesis (Fig ID and IE), suggesting that UBC9 increased
peptide supply to MHC class I molecules.
UBC9 was fIrst identified as a nuclear protein in yeast (123), and has been reported to
associate with many nuclear factors (126
, 149, 150). It seemed possible that UBC9 might
increase synthesis of the transfected antigens
, thus indirectly increasing peptide supply as
the proteins were degraded. However
, immunoprecipitation of full-length and cytosolic
ovalbum from transfected cells did not show any difference in protein levels in the
presence ofUBC9 (Fig ID). To fuher confi that UBC9 does not up-regulate MHC class
I antigen presentation by increasing protein synthesis
, I bypassed protein synthesis by
directly loadig ovalbum into the cytosol of cells by osmotic lysis o(pinosomes. Even
under these conditions UBC9-transfected cells expressed higher levels ofH- SIINEKL
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than control-transfected cells (Fig 6), confirmg that the effects of UBC9 on antigen
presentation are not mediated by increasing the
synthesis of antigen.
Although most researchers have found that UBC9 is not involved in protein
degradation, a few reports have demonstrated that UBC9 can lead to protein degradation
(123 , 127 , 128). Enhancing the degradation of an antigen can lead to generation of a
presented peptide (16). However
, UBC9 overexpression did not accelerate ovalbumin
degradation (Fig 8).
Many antigenic peptides are destroyed before they are presented by peptidases in the
cytosol and ER. It was possible that UBC9 was enhancing presentation by reducing the
degradation of these antigenic peptides. In collaboration with Dr. Tomo Sarc in Dr. A.
Goldberg s lab (Harvard Medical School
, Boston, MA) I examined the stabilty of pep tides
in UBC9-overexpressing cells. UBC9 overexpression did not protect peptides from
degradation in cytosolic extracts (Fig 21), or in intact cells (Fig 22). UBC9 
therefore does
not regulate MHC class I antigen presentation by protecting peptides from degradation.
1.1. UBC9 affects multiple steps in MHC class I antigen presentation
MHC class I antigen presentation is a multi-step pathway. In the cytosol
, proteins are
degraded by proteasomes
, generating oligopeptides. These peptides may be fuer
tred by aminopeptidases and transported into the endoplasmic reticulum lumen by the
transporter associated with antigen processing (TAP) complex. Tring ofN-extended
precursor peptides also occurs in the ER. Once generated
, 8- 10-residue long peptides bind
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to empty MHC class I heavy chain132-microglobulin complexes in the ER with the help of
tapasin. Chaperones, including GRP78 , calnexin, calreticulin, and ERp57 , assist MHC class
I assembly in the ER. I sought to identify the component(s) of the antigen presentation
pathway that was affected by UBC9 overexpression.
To help localize the effect(s) ofUBC9 on antigen processing, I hypertonic 
ally loaded
cells with different precursors of SIINEKL: SIINEKL extended at the N-terminus
(LEQLESIINEKL) or at the C-termus (SIIEKLT), or STIEKL itself. H-
SIINEKL levels on UBC9-transfected cells were always higher than control vector-
transfected cells, no matter which precursor was used. Ths was unexpected, since these
precursors have different requirements for proteolytic processing for the generation of,
SIINEKL.
In the absence of UBC9, SIINEKL antigen presentation was very ineffcient after
hypertonic loading of the C-termnal extended peptide STIEKLT
, while UBC9
overexpression increased H- STIEKL levels from ths precursor at least tenfold.
Similarly, when COS- cells were co-transfected with plasmids expressing UBC9 and C-
termnal extended SIINEKL, H- SIINEKL levels on UBC9 transfected cells were
much higher than on control vector transfected cells. In fact
, UBC9 overexpression
stiulated the greatest increase in presentation for the C-termally extended peptides
relative to all other constrcts , suggesting that it was affecting the C-termal trg step
(in addition to its other effects). The cleavage that generates the C-terminus of a presented
peptide is absolutely dependent on proteasomes (47), suggesting that UBC9 is affecting
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proteasome-mediated degradation. I also examned the unikely possibility that UBC9 might
promote protein degradation by a pathway other than the conventional ubiquitin-proteasome
pathway, that might more efficiently generate peptides suitable for MHC class I
presentation. However, the proteasome inhibitor MG 132 completely inhbited H-
SIINEKL expression on cells co-transfected with UBC9 and hypertonically loaded with
ovalbumin (Fig 9); this demonstrated that proteasomes are required for ovalbumin
degradation even when UBC9 is overexpressed.
On the other hand, the increase in presentation with LEQLESIINEKL, which can
bypass the proteasome and be trmmed by amoeptidases, suggested that UBC9 might also
affect aminopeptidases and/or some other step downstream of the proteasome. This seemed
paricularly plausible in light of a report that BH (an amnopeptidase that has been
associated with antigen presentation (49)) and that has been reported to associate with
UBC9 (202), although, I have been unable to detect any association between UBC9 and
BH). Ubc9 co-transfection increased the expression ofBH in cells. Moreover, transfectig
BH itself into cells augmented antigen presentation (Figue 20). Therefore, one of the ways
thatUbc9 may augment antigen presentation may be to increase BH and thereby the
trmmg of N -extended precursor peptides.
The peptide SIIEK; itself, which requires no proteolytic processing before
presentation, also showed enhanced presentation in the presence ofUBC9 , suggestig that
UBC9 may regulate peptide transporttion to ER lumen, and/or may affect antigen
presentation steps in the ER.
1.2. Does UBC9 increase peptide translocation from the cytosol to the ER lumen?
SIINEKL co-translationally targeted to the ER with an ER signal sequence bypasses the
standard antigen presentation cytosol-to-ER pathway, the TAP transporter
, but even with
ths constrct the H- STIEKL levels on UBC9 transfected cells were somewhat
higher than that on control vector transfected cells (Fig 15), although the effect is not as
marked as in cytosolic mingene transfected cells. This suggested that UBC9 affects steps
both in the cytosol (possibly TAP transport) and in the ER lumen that occurs after peptides
are generated. .
Taken together, these results suggest that multiple components of the antigen
presentation pathway may be regulated by UBC9. UBC9 had the strongest effect on full
length ovalbumn and the C-extended mingene
, suggesting that UBC9 affects proteasome
activity. However, UBC9 also increased H- STIEKL level in ER-targeted
STIEKL-transfected cells and in cells hypertonically loaded with SIINEKL peptide
suggesting that UBC9 may regulate cytosolic and/or ER components as well.
Imunofluorescence analysis confed these expectations. In UBC9-overexpressing cells
(but not in their untransfected neighbors), several components of the imunoproteasome
(LMP2, LMP7, and MECL1) were upregulated, which could account for the enhanced
generation of SIINEKL from proteasome-dependent precursors.
The LMP2and LMP7 genes are located in MHC class II region (11), which fIrst
suggested that they might playa role in antigen presentation
, though they were origially
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found not required for MHC class I antigen presentation (10 212). Upon IFNy treatment
the expression of MECL 1
, LMP2 , and LMP7 is induced and these subunts incorporate into
proteasomes (producing a paricle termed the "imunoproteasome ) (13) (184, 185 213).
Imunoproteasomes have different peptidase activities from constitutive proteasomes
although the ubiquitin-dependent protein degradation rate is not changed.
Immunoproteasomes have a preference for cutting proteins after hydrophobic and basic
, but
not acidic, amno acids, generating more peptides suitable for MHC class I binding (13). In
vitro experients showed that purfied imunoproteasomes do generate more precursors of 
antigenic peptides, which favors MHC class I antigen presentation (29). In LMP2 
and
LMP7 knockout mice
, MHC class I expression levels and CD8+ T cells are reduced
, and
immune response are impaired
, suggestig that LMP2 and LMP7 play important roles in
MHC class I antigen presentation and the imune response (28 , 32 , 33). Thus, the increase
in imunoproteasomes stimulated by UBC9 may contrbute to the large increase in
presentation of antigens that require cleavage by proteasomes.
But effects on the proteasome can not account for all my fmdings
, since UBC9
overexpression also increased presentation from proteasome-independent precursors.
Imunofluorescence microscopy also revealed that cells expressing UBC9 expressed higher
levels of TAP 1 compared to their UBC9-negative neighbors
, suggesting that UBC9 may
facilitate peptide translocation from the cytosol into the ER lumen. Ths may explain why
UBC9 overexpression increased H- STIEKL level on cells loaded with N-termal-
extended STIEKL and SIINEKL peptide, which are not dependent on the proteasome
for proteolytic processing.
118 ..,
The TAP complex, which is involved in transporting peptides from the cytosol to ER
lumen for MHC class I binding, is composed of two homologous proteins
, TAPI and TAP2
and helps to determine the peptides displayed on the cell surface and thereby affect T cell
imune responses (214, 215). TAP levels are normally relatively low
, but upon IFNy
treatment TAP expression is greatly upregulated (216), which in tu enhances peptide
transportation from, cytosol into ER lumen for MHC class I binding (217
, 218).
Upregulation of TAP and the presence of imunoproteasomes are still not suffcient to
explain the effect ofUBC9 on ER-targeted SIINEKL, since this precursor bypasses
cytosolic proteolysis and TAP transport. These effects could be 
explaied by the fuer
findig that tapasin was increased in UBC9 transfected cells.
Tapasin associates with both TAP and the MHC class I heaVY/132-m complex in the ER
and increases MHC class I antigen presentation by increasing peptide binding 
though
tethering TAP andMHC class I molecules together and even increasing TAP levels (219).
As with TAP, LMP2, LMP7 , and MECL- , tapasin is constitutively expressed at low levels
and can be up-regulated by several cytokines
, especially IFNy (220-222), which may
enhance peptide bindig in ER. The upregulation of tapasin could potentially account for
the effects ofUBC9 on presentation of SIINEKL from ER-targeted precursors.
It is importt to note that UBC9 overexpression did not increase the levels of leucine
aminopeptidase, and that levels of the ER chaperones calnexin
, calreticul, ERp57 and PDI
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(all of which interact with MHC class I durg matuation in the ER) are not changed in
UBC9-transfected cells. This is imortant for three reasons. First, this demonstrates the
specificity of the immunofluorescence microscopy, makng it unikely that the increased
intensity of TAP, tapasin, LMP2 , LMP7, and MECLI stainig were nonspecific. Second
, it
suggests that UBC9 specifically affects some
, but not all, of the steps in MHC class I
antigen presentation pathway. Third
, since LAP is interferon-inducible (48), this
demonstrates that UBC9 does not entirely replicate the effects of interferon treatment
, but
rather must affect proteins though a separate mechanism.
IFNy upregulates many genes associated with antigen processing, 
includig those 
show here are upregulated by UBC9
, by increasing their transcription. Could UBC9 act by
inducing IFNy? Ths seemed unlikely, since UBC9 did not affect levels of LAP
, which is
also IFNy-inducible. To futher exame this possibilty, I measured mRA levels of
MECLI in cells overexpressing UBC9
, using real-time PCR. Although the protein shows a
marked increase by immunofluorescent microscopy (Figue 23A), there was no change in
the mRA level compared to control-transfected cells (Figue 24). Ths shows that UBC9
does not act through IFy, and fuher suggested that UBC9 may act post-transcriptionally.
However, directly measurg the effect ofUBC9 overexpression on several of the
proteins in the class I pathway proved techncally diffcult
, for two reasons. First
, the
endogenous levels of the IFN-induced proteins MECLl
, LMP2, and LMP7 are
constitutively very low
, and even TAPI (which is constitutively expressed) is normally only
present at low levels. Tapasin
, was not detectable in COS-Kb cells, perhaps because of
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species differences in these Afrcan Green Monkey cells. I was therefore unable to detect the
endogenous proteins in immunoblots from COS-Kb cells, although R T 
- PCR, which is
generally much more sensitive than immunoblotting, detected 
mRA transcripts for these
genes. As well, overexpressing UBC9 by transient transfection results in only a 
miority of
cells overexpressing the gene: 20-30% of the total population in COS-Kb cells, and around
10% for Hela-Kb. Even if these cells strongly upregulated levels of a particular protein
, in
an immunoblot the increase would be diffcult to detect against the 
background of
untransfected cells. I used a vaccinia 
virs that expresses UBC9 to infect the COS-Kb cells
hoping that this would cause overexpression in a large proporton of the population.
However, these COS-Kb cells are not higWy inectable with vaccina vir, and a majority
of these cells consistently do not express high levels of recombinant genes from vaccinia
vis (personal communication from Ian York 
I therefore performed co-transfection experients
, transiently transfecting COS-
with both UBC9 and LMP2
, LMP7 , or MECLl , and imunoblotted for the co-transfected
protein. In these experients most cells will express both of the costransfected genes.
Imunoblots from these experients showed marked increases in the level ofLMP2
LMP7, MECLl , PA28a , and PA2813 protein in the presence ofUBC9, compared to control-
transfected cells (Fig 25), and pulse-chase experiments showed that the proteins were much
more stable in the UBC9-overexpressing cells than in the control-
transfected cells (Fig 28).
When I performed simlar experients with human tapasin, UBC9 itself did not
increase tapasin levels. However
, UBC9 did increased tapasin level when SUMO-2 was
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also co-transfected. This is consistent with the results that suggested that SUMO-
2 may be
involved in MHC class I antigen presentation. Tapasin is a very stable protein
, and even
with 8-hour chases we did not see any obvious protein degradation even in the absence of
UBC9. I was therefore unable to 
measure changes in degradation of this protein.
In summary, my fmdings with the different SIINFEKL precursors suggested that UBC9
overexpression affected proteasome fuction
, as well as ER components of the antigen
presentation pathway. The observation that UBC9 overexpression 
induces
immunoproteasome catalytic subunts
, TAP, and tapasin provides an explanation for these
fmdigs. While it is possible that UBC9 overexpression upreguates other components of
the ntigen presentation pathway, these effects we have documented could explain the
effects of UBC9 overexpression on antigen presentation.
1.3. How does UBC9 work?
Unlike other UBCs
, which conjugate ubiquitin to target proteins for proteasome-
dependent degradation
, UBC9 conjugates SUMO molecules to target proteins (131).
Sumoylation has multiple effects
, includig alterig subcellular localiation
, protein
stabilization, and trancriptional regulation (143
, 147, 149, 150, 161 209 223 224). As
with ubiquitination
, sumoylation is a multiple-step process in which the heterodimeric
SUMO-activating enze (composed ofSAEI and SAE2 (165) and UBC9 transfer SUMO
molecules to protein substrates (140).
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To know whether UBC9-mediated sumoylation is involved in the regulation 
ofMHC
class I antigen presentation proteins
, a mutant form ofUBC9, UBC90H, whose Cys93 has
been changed to serie
, was used to transfect COS- K cells. This mutant is unable to
conjugate SUMO to substrate proteins (147). UBC90H showed the same effect on antigen
presentation as did wild-tye UBC9, which initially seemed to to rue out the involvement
of sumoylation in MHC class I antigen presentation reguation. 
Interestigly, several papers
have reported that mutation of Cys93 in UBC9 does not affect its interaction with substrate
proteins (164, 173 , 174), even though most of the interacting proteins are sumo-
l substrates
(163), suggesting UBC9 may reguate the fuction of its tagets by diect interactions as
well as, or instead of, by sumoylation. On the other hand
, our SUMO transfection results
(Fig 34) suggested that sumoylation may be involved in MHC class I antigen presentation
regulation.
1.4. SUMO-2 may be involved in MHC class I antigen presentation regulation
In mammalian cells, there are at least thee SUMO moleclJles: SUMO- , SUMO-2 and
SUMO-3. To study which, if any, SUMO molecule(s) is involved in the regulation ofMHC
class I antigen presentation, CDI6-0V A-COS- cells were transfected with wild-tye and
mutant SUMO molecules. Only wild tye SUMO- , but not mutant SUMO-2 and other
SUMO molecules, increased the H- SIINEKL levels. on the cell surace (Figu 34),
suggesting that SUMO-2 regulates MHC class I antigen presentation.
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To determe whether SUMO-2 works together with UBC9
, I co-transfected COS-
cells with UBC9 and each of the three SUMO molecules
, includig for each wild-tye and
mutat forms in which the active conjugation sites were inactivated. If any SUMO
molecule is involved in MHC classI antigen presentation regulation
, its mutant form should
abrogate its fuction (225). Wild-tye SUMO- l and SUMO-3 behaved the same as mutant
SUMO- l and SUM03 in these experiments. However, wild-tye and mutat SUMO-
behaved differently in cooperating with UBC9. UBC9 and wild-
tye SUMO- , but not
UBC9 and mutant SUMO-
, increased H- SUNEKL levels on ovalbumin stable
transfectants, suggestig that UBC9 ismediating its effects by conjugatig SUMO-2 (Figue
33). These experients suggest that SUMO-2 and SUMOI and -3 have different fuctions
in vivo, though they are highly homologous
, and implicate SUM02 as the relevant SUMO
molecule in the regulation ofMHC class I antigen presentation.
However, H- SIINEKL levels were always lower on cells co-tranfected with both
UBC9 and SUMO-2 than on cells transfected with either UBC9 and SUMO-
independently: i.e. not only did we not see any additive effect ofSUMO-2 and UBC9 , co-
transfection slightly reduced the effect. (These results are summared in Table 3). If they
are working though each other, I would predict that they should result in an
additive/synergistic effect. One possible explanation for the reduced effect in double-
transfected cells is that in the double transfections
, the expression levels of both SUMO-
and UBC9 are lower than single transfections. In fact
, in double transfection experients
the UBC9 and SUMO expression levels were each much lower than single transfection with
either constrct alone (data not shown).
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Although UBC90H has the same effect as wild tye UBC9 on MHC class I antigen
presentation, there was no effect when COS- cells were co-transfected with both mutant
UBC9 and mutant SUMO-2. However, when mutant UBC9 was co-transfected with wild
tye SUMO- , H- SIINEKL levels were increased (sumared in Table 3). Again
these experients suggest that SUMO-2 and UBC9 affect the same step in MHC class I
antigen presentation pathway.
When I co-transfected MECLl , LMP- , and LMP-7 (as potential substrates for
sumoylation) with UBC9 and SUMO molecules
, I failed to detect any sumoylated protein.
However, it is techncally diffcult to detect sumoylated proteins in extracts of cells
, since
higWy-active isopeptidases in celllysates may rapidly remove SUMO molecules from their
conjugates; therefore my inability to show any sumoylation does not mean the proteins are
not, in fact, sumoylated.
5. Model for UBC9 regulating MHC class I antigen presentation
UBC9 overexpression clearly upregulates MHC class I antigen presentation. Ths is
accomplished at least parly by alterig the activity of proteasomes, by increasing LMP2
LMP7 , and MECL- , which incorporate into proteasomes and alter the catalytic activity in
such as way as to increase the production of antigenic peptides and their precursors. BH
levels may also be increased, which may help to tr antigenic peptides. UBC9
overexpression also increases TAPI and tapasin levels
, which wil increase transport of
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peptides into the ER and enhance their association with newly-synthesized MHC class I
molecules. The effect ofUBC9 is mediated
, at least for some of these proteins
, by
stabilzing the protein and reducing degradation.
The simplest explanation for UBC9' s effect on these proteins is that it is mediated
directly by sumoylation. Unlike ubiquitination
, it is diffcult to generalize the effects of
sumoylation on proteins. For transcription factors
, sumoylation always seems to repress
their activity (158 , 226, 227) (228). Subcellular localizationis another importt but distinct
fuction of sumoylation. The best example for this is cytosol-nuclear transport (130
, 229). I
tested whether UBC9 causes ovalbumin to be transported to specific subcelluar
localizations , such as PML oncogenic domains (PODs), which accumulate
imunoproteasomes and P A28 upon IFy treatment (230) and are therefore candidates for
antigen processing; however
, I did not find that ovalbum wasco-localized with PML
protein (data not shown). Our minigene transfection and peptide loading experients also
suggested that UBC9 does not regulate MHC class I antigen presentatipn by sumoylation of
the antigen, since SIINEKL, whose presentation is enhanced by UBC9
, is very unlikely to
be a SUMO substrate.
Sumoylation with SUMOI has been shown to stabilize some proteins (161). The
mechanism for this stabilzation is not clear. In some cases (e.g. when SUMO 1 is
conjugated to I-KBa), it seems that the SUMO molecules are ,
conjugated to the same lysines
that would otherwise be used by ubiquitin
, and by blockig ubiquitiation proteasome-
mediated degradation (161). UBC9 overexpression increases the levels of several MHC
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class I pathway-associated proteins. Since we were 
unable to detect sumoylation of these
proteins, it is difficult to say whether sumoylation of these proteins was blockig
ubiquitination.
UBC90H, a mutant of UBC9 that is unable to conjugate SUMO to substrates
, increases
MHC class I antigen presentation as well as wild-
tye UBC9, which argues that UBC9
increases substrate levels by direct interaction rather than sumoylation. However
, mutant
SUMO-2 transfection, in contrast to wild-tye SUMO- , faiied to increase MHC class I
antigen presentation, suggesting that SUMO molecule is involved in UBC9 fuction in
MHC class I antigen presentation. This raises a more complicated model where UBC90H
might be workig in concert with endogenous wild tye UBC9 or some other UBC. For
example, UBC90H may dock to substrates only after a SUMO-2 molecule is already
attached (which in our system would be conjugated by the endogenous wild-
tye Ubc9) (Fig
46).
In normal cells, few proteins are conjugated to SUM02 and 3 in the steady
state (172),
although in stressed cells SUM02 and 3 are rapidly conjugated to high-molecular-weight
proteins (172). It is not known whether the low level of conjugation found in normal 
cells is
because the SUMO molecules are not conjugated
, or because they are conjugated and then
rapidly removed from taget proteins by desumoylating 
enzes (231 , 232). The presence
in normal cells of large amounts of isopeptidases that effciently remove SUMO molecules
from their substrates (233) suggests that the latter may be the case. This provides 
a possible
explanation for two points. First
, according to my model above
, UBC9 or UBC90H must
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Sumo-
stablizzation
Ubc90H
Fig 46. Model for UBC9 stablize target proteins. Either overexpressed or endogenous
UBC9 conjugate SUMO-2 to target protein. The SUMO-2 conjugated proteins can be
physically associated by either wildtye or catalytically inactive UBC9, which stablize
the target proteins.
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interact with sumoylated proteins; yet I and others have found little evidence for
sumoylation of these or other proteins. Ifproteins are sumoylated transiently, then UBC9
(or UBC90H) could interact with the proteins and alter their fuction durng their
sumoylated phases. Second, I found that overexpressing SUM02 (but not mutant SUM02
that cannot be conjugated to substrates) enhances antigen processing. IfSUM02 is not
normally conjugated to substrates, it is diffcult to account for this, since overexpressing
SUM02 would simply increase the pool of free SUM02. However, if there is normally
constant sumoylation and desumoylation, then increasing the pool of free SUM02 by
transfection should push the equilbrium toward conjugation, effectively increasing the
sumoylated phase for substrate proteins, and increase the period durng which endogenous
or transfected UBC9 could interact with the proteins. According to this reasoning, mutant
SUM02 , which is unable to interact with substrate proteins, would not enhance antigen
processing; this is what we observed.
Finally, if cells are co-transfected with both mutat UBC9 and mutat SUMO-
UBC90H wil not conjugate the endogenous wild-tye SUMO- , and transfected mutant
SUMO-2 wil compete for the endogenous wild-tye UBC9 with endogenous wild-tye
SUMO-2 for conjugation to taget proteins. As a result, taget proteins wil not be
sumoylated, and neither the wild-tye nor the mutant UBC9 wil interact with the taget
proteins.
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Although, at least in COS cells, there are high level of SUMO-2 and SUMO-
molecules, their fuction in vivo is not known. My in vivo transfection experiments suggest
that SUMO-2 may be involved in protein degradation and stablization.
While many proteins are regulated by sumoylation, there are also examples of proteins
that are apparently regulated by direct interaction with UBC9, including the DNA repair
proteins RA51 and RA52 (132), cell cycle regulatory factors CLB2 and CLB5 (an S-
phase cyclin) (123), and the glucocorticoid receptor (147). Interestingly, many of these
substrates are also found to be sumoylated. For example, it was found that glucocorticoid
receptor is post-translationally modified by SUMO- l (234 235). Since I found that
overexpression ofUBC90H (which cannot conjugate SUMO to target proteins) affects
antigen presentation to the same extent as UBC9, it is also possible that Ubc9 is working in
our system fully or in part independently from sumoylation.
6. UBC9 knockout does not decrease H- SIINEKL level
How physiologically significant is UBC9' s effect on MHC class I antigen presentation?
I attempted to addresse this question with siRNA, which has been used to knock out many
genes in vivo (203-205 , 206, York, 2002 #596). I successfully knocked out UBC9 with
siRNA, but when UBC9 was eliminated, the cells stopped growing, and plasmid
transfection efficiency was very low. These results suggested that UBC9 is essential for
mammalian cell viability, which is consistent with recent observations (236). Elimination
ofUBC9 had no effect on presentation of full-length ovalbumin, but increased presentation
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ofER-tageted SIINEKL and of MSIINFEKL. One would expect elimination ofUBC9 to
have opposite effects to overexpression, but both treatments increased antigen presentation.
It seemed possible that overexpression ofUBC9 had a dominant-negative effect, which
would lead to the same effect as siRNA-mediated elimination. However, if this was the
case , the siRNA results should precisely mirror those of the overexpression studies, while in
fact not all the siRNA results were consistent with my UBC9 overexpression experiments
in which UBC9 has the strongest effect on full-length ovalbumin, but had relatively little
effects on SIINEKL minigene and ER targeted SIINEKLminigene.
Because elimination of UBC9 induced cell death, these studies are not definitive, and
the results may reflect non-specific effects of cell stress or death. However, the lack of an
effect on full-lengt ovalbumin when UBC9 is eliminated is generally consistent with the
model presented above. Since cells normally express very low levels of immunoproteasome
components, reducing them (as might happen if UBC9 is eliminated) should not affect
ovalbumin processing. It is also possible that UBC9 knockout decreases the generation of
suitable peptides, which may give ER-targeted or mini gene-generated SIINEKL more
chance to bind to MHC class I molecules by reducing competition. In fact, I did find that
UBC9 knockout increased ER-targeted SIINEKL and MSIINFEKL, but not full-length
ovalbumin, presentation (Fig 30). However, the overall MHC class I expression level was
increased in UBC9 knockout cells, implying that generation of other peptides was also
increased (rather than reduced). It is possible that UBC9 knockout leads to cell stress or
other non-specific effects which may increase MHC class I antigen presentation.
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It is not possible to fully study the fuction ofUBC9 on MHC class I antigen
presentation by knocking out UBC9, since UBC9 seems to be critical for cell viability. One
alternative is to find the SUMO conjugation sites of targeted proteins. By comparing the
SUMO conjugation site sequence ofUBC9 target proteins, Sampson et al. found the
consensus sequence of SUMO- l conjugation is PsiKXE , in which Psi stands for a large
hydrophobic amino residue, and X stands for any amino acid (237). By mutating the
conjugation sites, it may be possible to study the fuction ofUBC9 on MHC class I antigen
presentation. UBC9 may also increase protein levels via an indirect effect. For example
within MECL- , LMP2 and LMP7, UBC9 may increase anyone of them, which may
stabilize the other two subunits by increasing incorporation into immunoproteasomes; or
UBC9 may increase TAP I levels by increasing tapasin (219). The fact that UBC90H
increases K SIINEKL level also hints that sumoylation might not be not essential. More
work is needed to fmd the mechanism by which UBC9 increase MHC class I antigen
presentation.
7. Biological signficance.
While little is known about the effects of modification with SUMO-2 and - , it is likely
that their targets and fuctions are different from SUMO- I. For example , SUMO- l is
predominately found conjugated to nuclear membrane proteins , while SUMO-2-conjugated
proteins are located in the nuclear bodies and SUMO-3-conjugated proteins are mainly
found in the cytosol (238). Unlike SUMO- , which is constitutively mainly found
conjugated to proteins, a large pool of free SUMO-2 and SUMO-3 can be found. When
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cells are stressed by heat shock or oxidative stress , however, SUM02 and 3 rapidly become
conjugated to high-molecular-weight proteins (172 , 238).
One source of cell stress is virus infection, which is often associated with massive viral
protein accumulation and induction of the unfolded protein response (239, 240). The
unfolded protein response causes, among other things , a rapid and potent inhibition of
translation of cellular proteins, and many viral infections also directly inhibit host protein
synthesis through other means. Under these circumstances, therefore, when an immune
response would be most appropriate, new synthesis of proteins required for antigen
processing would be inibited.
We speculate that under conditions of cell stress, UBC9 conjugates SUM02 or SUM03
to proteins associated with antigen processing. These sumoylated proteins are degraded
much less rapidly than unconjugated versions, so that levels of these proteins are relatively
spared and the cell can maintain antigen presentation even while other protein levels are
reduced. If the cellular stress was in fact the result of viral infection, then recogntion of the
infected cells by CTL wil result in IFNy expression and infected cells may also release tye
II IFN s. These cytokines induce transcriptional upregulation of genes involved in antigen
processing, so that the infected cell can enter a fully-effective antiviral mode. It has been
reported that IFNy also induces UBC9 expression (208) (although I did not find the
increased UBC9 protein expression level), so that IFNy treatment may also help to stabilize
pre-existing proteins as well as induce synthesis of new ones. According to this model
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sumoylation is a rapid response to cell stress that maintains antigen presentation even while
overall protein expression is reduced.
My experiments showed that UBC9 overexpression regulates MHC class I antigen
presentation. When using ovalbumin as a model antigen, UBC9 overexpression markedly
increases the levels of the immunodominant epitope SIINEKL on the cell surace.
However, in most of the cells I examined, the total level ofMHC class I on the cell surace
did not change nearly as much, implying that peptide supply in general was not increased to
the same extent as SIINEKL. This in tu suggests that UBC9 effects on antigen
presentation may actually inhibit the presentation of some epitopes, rather than universally
enhancing them.
2. HSP27 overexpression inhibits MHC class I antigen presentation
HSP27 is expressed in a variety of tissues in the absence of stress and is involved not
only in apoptosis, such as virus-induced cell death (85), but also in cell surival, such as in
injured sensory and motor neuron surival and in TN-mediated apoptosis (86 87). Human
HSP27 is a potent inducer of IL- l 0 in human monocytes, suggesting a possible role in
imune responses (88). HSP27 expression has been shown to confer resistance to cell
death by interferig with apoptosis in response to multiple stresses (86, 241 , 242).
Phosphorylated HSP27 has been shown be involved in cytoskeletal rearangements
suggesting that HSP27 is involved in cell movement or paricle transporttion within cell
(243 , 244).
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While studying UBC9' s mechanism of action, I examined some proteins that are known
to interact with UBC9. In Drosophila, HSP27 has been shown to interact with UBC9 (210).
Based on the high sequence homology between mammalian and Drosophila UBC9 (83%
identity), we expected that mammalian UBC9 would also interact with HSP27. When a
protein of approximately the right molecular weight was found to be conjugated to SUMO
in the presence ofUBC9 overexpression (even though this later proved to be UBC9 itself, I
therefore asked whether HSP27 , like UBC9, affects MHC class I antigen presentation.
HSP27 overexpression markedly reduced H- SIINEKL levels when COS- cells were
hypertonically loaded with ovalbumin protein. As well as showing that HSP27
overexpression inhibits MHC class I antigen presentation, these results suggested that
HSP27 does not inhibit MHC class I antigen presentation by inibiting protein synthesis.
HSP27 overexpression inibited MHC class I antigen presentation in E36- cells
transfected with plasmids expressing many forms of SIINEKL precursors, includig full-
length ovalbumn, ER-targeted SIINEKL, and N-extended and C-extended SIINEKL, as
well as MSIINEKL. The effect on ER-tageted SIINFEKL seemed paricularly
significant, since this constrct tagets SIINEKL directly into the ER lumen, while HSP27
is a cytosolic protein. The results with this constrct show that HSP27 does not affect
peptide transporttion from the cytosol to the ER via the TAP complex. It is also very
unlikely that HSP27 inhibits MHC class I antigen presentation by inhibiting protein
degradation, since constrcts that are dependent on different proteolytic pathways (i.e. the
proteasome and aminopeptidases) were all affected. It seems that HSP27 affects steps of
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MHC class I antigen presentation that are in the ER or after the ER, e.g. protein
transportation to the cell surace.
When COS-7 cells were co-transfected with HSP27 and H- or H- , the levels of
both H- and H- were lower than on cells transfected with control vector (Fig 45).
However, HSP27 overexpression did not decrease surace expression of the human MHC
class I allele HLA-A3 (Fig 39 , 45), suggesting that the effects ofHSP27 on MHC class I
antigen presentation differ depending on the MHC class I allele. As well, Hsp27
overexpression decreased levels of influenza hemagglutinin on cell surace, suggesting
HSP27 inhibits transporttion of some membrane proteins, rather than specifically affecting
MHC class 
HSP27 is a phosphorylated protein, in which there are three potential phosphorylation
sites: S15 , S78 and S82. To know whether HSP27 phosphorylation is involved in regulating
MHC class I antigen presentation, point mutations were introduced to generate SI5A, S78A
and S82A. None of these mutations affected HSP27's effect on MHC class I antigen
presentation, suggesting that protein phosphorylation is not involved in HSP27 fuction in
MHC class I antigen presentation. However, since I did not make double or trple
mutations, I can not rule out the possibility that these phosphorylation sites have redundancy
in regulating HSP27 fuction.
Since UBC9 has been reported to interact with HSP27, we speculated that UBC9 may
increase MHC class I antigen presentation by conjugating SUMO-2 molecules to HSP27
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and inhibit its fuction. However, I failed to fmd sumoylated HSP27 protein by
immunoprecipitation or immunoblotting. Also, after introducing point mutations to HSP27
in which all potential sumoylation sites were individually mutated from lysine to serine
there was no difference in HSP27's effect on MHC class I antigen presentation. These
findings suggested that UBC9 does not regulate MHC class I antigen presentation by
sumoylating HSP27. However, again, since I did not mutate all the lysines simulataneously,
it is possible that sumoylation ofHSP27 is redundant, and that more than one lysine can be
sumoylated with the same effect. It is also possible that HSP27 inhbits MHC class I
antigen presentation only when it is not sumoylated, and that overexpressing even wild-tye
HSP27 overwhelms the sumoylation machinery and results in excess unsumoylated HSP27.
In that case, mutating the sumoylation sites would not affect the inhibition.
HSP27 exists in vivo as multimers ranging from dimers to )-700-kDa oligimers. Upon
phosphorylation, HSP27 oligomers are dissociated and regulate actin filaments by
association. HSP27 plays a very significant fuction in regulation of the actin cytoskeleton
(245). In fact in vitro experiments showed that unphosphorylated HSP27 inhibited actin
polymerization (246). It is possible that this mechanism might account at least in part for
HSP27s effect on antigen presentation: HSP27 overexpression might alter cytoskeleton
formation, which might playa role in the transport of membrane proteins to the cell surace.
HSP27 knockout inhibits MHC class I antigen presentation
To know the physiological importce of HSP27 in MHC class I antigen presentation
in vivo, we used siRNA to knock down HSP27. HSP27 was successfully knocked down by
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at least 95% in COS- cells (Fig 43). Surrisingly, HSP27 knockdown, as with
overexpression, impaired MHC class I antigen presentation. HSP27 knockdown decreased
not only generation ofH- SIINEKL complexes from all full-length ovalbumin and
SIINFEKL peptide precursors , but also overall H- levels, suggesting the significance of
HSP27 in MHC class I antigen presentation.
Therefore both overexpression and reduction ofHSP27 expression had a negative effect
on MHC class I antigen presentation. In the absence ofHSP27 , the cytoskeleton may be not
regulated properly, which may also affect protein transport to the cell surace. However
this would not be consistent with our fmding that the surace expression of HLA-A0302
was not affected by the loss or overexpression of HSP27. It is noteworthy that (as with
UBC9 siRNA) when HSP27 was knocked out, the cells became sick and stopped growing,
suggesting that HSP27 is essential for cell viability, which may be related to its fuction in
modulating cytoskeletal fuctions. HSP27 deficiency results in death of embryonic stem
cells (247). The apparent requirement for HSP27 for cell viability means the siRNA results
should be interpreted with caution.
How does HSP27 affect MHC class I antigen presentation? As I noted above, since
HSP27 overexpression affects the presentation of SIINEKL from ER-targeted SIINEKL
it must affect some steps after peptides have been transported into ER rather than the
peptide-generation aspects of the pathway. This possibility was supported by the fmding
that HSP27 decreased influenza virus hemagglutinin expression at the cell surace. I
propose that HSP27 may regulate MHC class I complex transportation by regulating the
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cytoskeleton. It is possible that when HSP27 is over-expressed, it acts as a dominant
negative form (perhaps because it overwhelms the sumoylation machinery, and only the
sumoylated form is fuctional), which confers a very similar phenotye to HSP27
knockdown.
Several heat shock proteins have been reported to be involved in MHC class I antigen
presentation, including Hsp70 and gp96 (79 , 80). A role for HSP27 in MHC class I antigen
presentation has not been previously reported. Unlike other HSPs, HSP27 is not stress-
inducible (84). Although it has been reported that Drosophila UBC9 interacts with HSP27, I
did not find human UBC9 interact with HSP27 in my immunoprecipitation experiments.
This may be fuher studied by a yeast two-hybrid approach. But it is very unlikely UBC9
regulates MHC class I antigen presentation via regulating HSP27. Since HSP27 inibit all
SIINEKL precursors presentation, and influenza HA surace expression, HSP27 seems
inibit protein traveling from ER to cell surace
What is the biological significance?
The biological signficance ofHSP27 overexpression remains unclear. The effect of
HSP27 overexpression on HA suggests that it is not specific for the immune system
, but
rather may playa general role in protein transport. The fact that HSP27 siRNA-treated cells
are not viable supports this possibility. The observation that overexpression ofHSP27 does
affect the expression of some MHC class I alleles may be relevant if, in normal cells , HSP27
levels are fuctionally regulated. The connection to sumoylation (described by D. Joanisse
(210), although in our experiments we were unable to detect sumoylated HSP27) suggests
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one possible means for regulating HSP27
, if either only sumoylated, or only non-
sumoylated, HSP27 is fuctional. My finding that, in general, UBC9 and SUMO-2 enhance
antigen presentation leads to the prediction that non-sumoylated HSP27 may inhibit MHC
class I expression on the cell surace. In that case, one of the ways through which UBC9
overexpression enhances antigen presentation would be by inhibiting HSP27's inhibition of
surace transport. Since cell stress does not directly regulate HSP27 levels (85
, 87)UBC9
may provide a link between certain forms of cell stress and fuctional regulation ofHSP27.
It is also possible that HSP27 can be more directly regulated. For example
, when
macrophages were infected with Mycobacterium tuberculosis
, HSP27 was down-regulated
(248). This may represent a mechanism by which infected cells regulate antigen
presentation in response to an intracellular pathogen. Conversely, HSP27 overexpression
which reduces the expression of some MHC class I alleles
, may be a mechanism for
immune evasion by tuors and viruses. In fact, many cancer and tuor cells have been
reported to express high levels ofHSP27 (249, 250). It wil be of interest to examine the
role of this HSP27 overexpression on antigen presentation in these cells. As well
examining HSP27 levels in cells infected by varous viruses may help explain the role of
this protein in antigen presentation.
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Appendix
The following are some recipes for some solutions used in my experiments.
Loading buffer:
First mix:
85 g sucrose
0.4 ml I M Hepes
in 30ml RPMI1640.
heat to 37 C. Then melt 2 bottles of PEG (2mg/ottle) at 56 , and add to the above.
Fil up to 40 ml with RPMIl640 and filter though 0.
Hypotonic medium:
60% (v/v) RPMI1640, no additive
40% (v/v) ddH
Filter through 0.
SP-Optimem
Optimem-500 ml bottle (Gibco BRL 31985)
5 ml nutrdoma (Boehrnger Manheim 1011370)
11 M 2-
10ml L-Glutamine
5 ml Pen Strep
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HCM
in 500ml RPMI1640, supplemented with 25 Iv of 1M 2- , 10 ml ofL-Glutamine, 5
ml of Non-essential AA, 5 ml PSF, 5 ml of HE PES , 50 ml ofFBS.
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